Dynamics of Regulatory T cells in Liver Transplantation by Demerkiran, A. (Ahmet)
Dynamics of Regulatory T cells 
in Liver Transplantation
Ahmet Demirkiran
The studies described in this thesis were performed at the Department of Surgery, 
Erasmus MC, Rotterdam, the Netherlands.
Financial support for this research was provided by a Revolving Fund from the Erasmus MC and 
a Gastrostart grant from the Dutch Society of Gastroenterology and Hepatology
Financial support for the publication of this thesis was kindly provided by Roche Nederland B.V., 
Novartis Pharma B.V., Wyeth, C & E Bankiers, Merck Sharpe & Dohme, Tyco Healthcare B.V., 
Stichting Lever Onderzoek, Nederlandse Transplantatie Vereniging, Genzyme en Astellas Pharma B.V., 
producent van o.a. Advagraf en Prograft
Cover design by Elwin J. Bes
Lay-out design by Ayhan Beyazıt
Printed by Optima Grafische Communicatie, Rotterdam
ISBN 978-90-8559-323-2
© Ahmet Demirkiran, Rotterdam, 2007
Dynamics of Regulatory T cells in Liver Transplantation
Dynamiek van Regulatoire T cellen in Levertransplantatie
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
Prof.dr. S.W.J. Lamberts
en volgens besluit van de College voor Promoties
De openbare verdediging zal plaatsvinden op 
woensdag 28 november 2007 om 13:45 uur
door
Ahmet Demirkiran
geboren te Rotterdam
PROMOTIECOMMISSIE
Promotor:  Prof.dr. H.W. Tilanus
Overige Leden:  Prof.dr. J.N.M. Ijzermans
   Prof.dr. W. Weimar
   Prof.dr. J.D. Laman
   
Copromotor:  Dr. L.J.W. van der Laan
CONTENTS
Part I General introduction
Chapter 1 Introduction and outline 9
Chapter 2 Impact of immunosuppressive drugs on CD4+CD25+Foxp3+ 
regulatory T cells: Does in vitro evidence translate to the 
clinical setting?
19
Part II Regulatory T cells in peripheral blood
Chapter 3 Decrease of CD4+CD25+ T cells in peripheral blood after liver 
transplantation: association with immune suppression
37
Chapter 4 Low circulating regulatory T-cell levels after acute rejection in 
liver transplantation
45
Chapter 5 Changes of circulating CD4+Foxp3+ regulatory T cells after 
conversion from calcineurin inhibitor to mycophenolate mofetil 
in liver transplantation
61
Part III Regulatory T cells in the liver
Chapter 6 Allo-suppressive donor CD4+CD25+ regulatory T cells detach 
from the liver graft and circulate in recipients after liver 
transplantation
79
Chapter 7 Low IL-10 gene expression levels in liver and blood during 
acute rejection after liver transplantation
97
Chapter 8 Intrahepatic detection of Foxp3 gene expression after liver 
transplantation using minimally invasive aspiration biopsy
111
Part IV Closure
Chapter 9 Summary and discussion 123
Chapter 10 Dutch summary (Samenvatting) 135
Appendix Acknowledgements (Dankwoord) 145
Curriculum Vitae Auctoris 149
List of publications 151

Part I 
General introduction

Chapter 1
Introduction and outline

LIVER TRANSPLANTATION AND TOLERANCE 
Liver transplantation has become the only definitive therapy for end stage liver disease. In the 
early days of liver transplantation, short term patient and graft survival was strongly depen-
ding on the surgical technique and the immune system of the recipient. The first successful 
liver transplantation was performed by Dr. Thomas Starzl in 1967 (1). After the enhancement 
of the surgical technique with improvement of preservation solutions and operative strategy, 
adequate anti-rejection treatment was the key factor to further progress. A major step forward 
was set after the discovery of calcineurin inhibiting immunosuppressive agents: cyclosporine 
A and later tacrolimus. Cyclosporine was first introduced by Sir Roy Calne and colleagues in 
1979 (2), causing a prominent improvement of patient and graft survival. Since then calcineu-
rin inhibitors are universally applied in the immunosuppressive treatment following liver trans-
plantation. Presently, the success of solid-organ transplantation depends on the continuous 
administration of immunosuppressive agents, which unfortunately are toxic and cause severe 
complications. These complications include increased risks for opportunistic infections, ma-
lignancy, cardiovascular and renal complications as well as a variety of agent-specific side 
effects. Immunosuppression-related complications are nowadays the most important determi-
nants of long-term patient survival and quality of life (3, 4). 
Since the early days of organ transplantation, the immune response against the donor organ 
has been a major topic of transplantation research. The ultimate goal is the achievement of 
a state of immunological non-responsiveness against the donor antigens in recipients. This 
state, also referred to as transplant tolerance, has been reported in a number of transplant 
patients, who did not comply and stopped using the immunosuppressive drugs. Several stu-
dies showed that a subset of patients is tolerant for the graft and theoretically does not require 
any immunosuppression. In liver transplantation 10 to 30 percent of the recipient have been 
shown to be tolerant and showed no signs of rejection after immunosuppression withdrawal 
(5-8). In addition, four out of ten transplant recipients are thought to be over-immunosup-
pressed, causing unnecessary exposure and severe complications due to side effects. Safe 
adjustments and weaning of immunosuppression without rejection requires prognostic tests 
that identify patients who are hypo-responsive or even non-responsive (tolerant) for their graft. 
So far, no such test exists and therefore all transplant recipients are treated with immunosup-
pressive agents.
Although the exact mechanisms of transplant tolerance are still not fully understood, several 
pathways have been described which can contribute to immunological non-responsiveness. 
These include active immune regulation, chimerism, T-cell and B-cell deletion, anergy and 
clonal exhaustion. The variety of the named mechanisms illustrates the complexity of under-
standing transplant tolerance. In the past decade active immune regulation has emerged as 
an exciting possible candidate to help understand immunological unresponsiveness against 
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self- and non-self antigens. This thesis focuses on regulatory T cells that have become known 
as key players in immune regulation and are characterised by their immunosuppressive acti-
vity (9, 10). By improving the understanding of active immune regulation, patients who do not 
mount an immune response against the donor organ may be identified. Subsequently, these 
patients may be withdrawn from immunosuppressive treatment, as immunosuppressive treat-
ment becomes redundant. 
Immune activation and regulation
The immune reaction against donor tissue (antigens), also called the allo-response, is the 
driving force of graft rejection. Rejection is an inflammatory reaction in the donor organ that 
involves different cell types. Allo-reactive T cells play a key role in the immune reaction and 
can be subdivided into two lineages; the helper T cells (CD4+) and the cytotoxic T cells (CD8+). 
CD4+ T cells are known for their central role in the initiation of an immune response and their 
ability to coordinate the differentiation and effector function of other immune cells, while CD8+ 
T cells are characterized by their cytotoxic activity. 
The activation of T cells depends on a cascade of signals. First the interaction of the T cell 
and the antigen presenting cell: the T-cell receptor (TCR) binds to the major histocompatibility 
complex (MHC) presenting the antigen. When TCR triggering is accompanied by a co-stimu-
latory signal, cytokine genes are activated causing production and release of cytokines, an 
essential element in the course of immune activation. IL-2 is one of the most important acti-
vating cytokines causing activation, proliferation and differentiation of T cells. The critical role 
of IL-2 in mediating an immune response against the donor organ is well demonstrated by the 
action of immunosuppressive drugs. Cyclosporin A and tacrolimus suppress the allo-response 
by inhibiting calcineurin signalling, which is required for IL-2 production by T cells. Anti-IL2 re-
ceptor blockers, which have helped to further reduce the incidence of acute rejection, prevent 
binding of IL-2 to its receptor thereby prohibiting downstream signalling. Steroids interfere 
with cytokine gene activation, including IL-2, and rapamycin inhibits the IL-2 mediated signal 
transduction pathway. Once adequate activation has occurred, T cells migrate to the donor 
organ and mediate several effector mechanisms, such as cytotoxicity, delayed-type hypersen-
sitivity and antibody production. These effector mechanisms damage the donor organ and are 
recognized as acute rejection (11).
Identification of the counterparts of effector T cells, the suppressor or also called regulatory T 
cells, has inspired transplantation biologists to exploit the role of these cells in controlling allo-
responses. Experimental transplantation models have shown an important role for regulatory 
T cells in the induction and maintenance of transplant tolerance by suppressing allo-reactive T 
cells (12). Extensive research revealed several subsets of regulatory T cells including CD4+ T 
cells, CD8+ T cells (13, 14), CD8+CD28- T cells (15) , NKT cells (16, 17) and CD4- CD8-  double 
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negative T cells (18). Accumulating evidence, however, suggests that immune regulation of 
allo-antigen-driven immune responses is enriched in the CD4+ T-cell population. As mentioned, 
CD4+ T cells are crucial in directing and initiating an immune response and therefore this thesis 
aimed to study CD4+ regulatory T cells in clinical liver transplant recipients, in particular the IL-2 
receptor α-chain expressing (CD25+) CD4+ T cells. 
Although multiple CD4+ regulatory T cells have been described, including IL-10 producing Tr1 
cells and TGF-β producing Th3 cells, the CD4+CD25+ regulatory T cells have emerged as the 
most potent suppressors of allo-responses. This subset of regulatory T cells is characterized 
by the expression of CTLA-4 (a co-inhibitory molecule), CD45RO, CD27, CD62L, CD122 and 
GITR (19-22). All of these markers, however, are not specific for CD4+CD25+ regulatory T cells 
as they are also expressed on activated or resting T cells. The identification of the nuclear 
transcription factor Foxp3 in CD4+CD25+ regulatory T cells has facilitated the differentiation of 
these cells from recently activated or resting T cells (23, 24). Functional studies have shown 
that CD4+CD25+ regulatory T cells can inhibit CD4+ and CD8+ T cell alloresponses and in expe-
rimental models infusion of these cells have been shown to prevent graft rejection (12).
AIM AND OUTLINE OF THE THESIS
Even though an important role of CD4+CD25+ regulatory T cells have been described in expe-
rimental models of transplant tolerance, evidence in clinical transplantation is still limited. This 
thesis aimed to identify and characterize CD4+CD25+ regulatory T cells in circulation and in 
the liver graft after clinical liver transplantation. Better understanding of the function of this cell 
subset in relation to allo-reactive T cells may be used as a prognostic tool to identify transplant 
tolerance and provide tailor-made immunosuppression to individual transplant recipients.
PART I
In chapter two the in vitro and in vivo effects of immunosuppressive therapy used in solid organ 
transplantation on the function and survival of CD4+CD25+Foxp3+ regulatory T cells are revie-
wed. Recent evidence suggests that immunosuppressive therapy not only inhibits effector T 
cells but also affect regulatory T cells, which may have negative consequences for the induc-
tion of transplant tolerance. 
PART II
Part two includes three studies involving the hemodynamics of regulatory T cells. In chapter 
three and four the proportion of CD4+CD25+ regulatory T cells within the helper T cell population 
was determined in relation to immunosuppressive therapy, to the occurrence of acute rejection 
and to time after liver transplantation. In chapter five we studied the effect of conversion from 
a calcineurin inhibitor based immunosuppressive treatment to a mycophenolate mofetil based 
treatment on regulatory T cells and on calcineurin inhibitor associated side effects. 
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PART III
In the third part of this thesis the presence of regulatory T cells in the donor liver was studied. 
In chapter six the phenotype and suppressive capacity of hepatic CD4+CD25+ regulatory T 
cells, migrated from the liver graft into the perfusate solution at time of transplantation, were 
investigated. Furthermore, the presence of these donor-derived regulatory T cells in recipient 
blood was monitored. In chapter seven and eight, intrahepatic regulatory T cells are investiga-
ted using liver aspiration biopsy samples taken early and late after transplantation. 
PART IV
In chapter nine and ten the results of this thesis are summarized and discussed. The potential 
use of regulatory T cells and future perspectives are denoted.
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Chapter 2
Impact of immunosuppressive drugs on 
CD4+CD25+Foxp3+ regulatory T cells: 
Does in vitro evidence translate to the clinical setting?
Ahmet Demirkiran, Thijs K. Hendrikx, Carla C. Baan and Luc J.W. van der Laan
Transplantation, Conditionally accepted 
ABSTRACT
The success of solid-organ transplantation mainly depends on the continuous administration 
of immunosuppressive drugs to prevent rejection. The currently prescribed immunosuppres-
sive medication targets the immune system in a nonspecific fashion, which leads to many 
debilitating side effects influencing patient- and graft survival. Therefore, it is essential to mi-
nimize immunosuppressive therapy. To accomplish this, therapeutic strategies to induce and 
maintain transplant tolerance have to be developed. One such strategy would be to facilitate 
the induction of alloantigen specific immune regulation by regulatory T cells (Treg). Results 
from recent experimental studies indicate that several commonly used immunosuppressive 
drugs have detrimental effects on the induction and function of Treg while other drugs seem 
to spare these cells or may even be beneficial. These differential effects may be explained 
by differences in signaling pathways between Treg and effector T cells. In this review we will 
discuss whether the effects of immunosuppressive drugs on CD4+CD25+Foxp3+ Treg in vitro 
translate to the clinical setting. A greater understanding of the impact of immunosuppression 
on Treg may help to create future opportunities to manipulate the host immune response 
against alloantigens in order to achieve operational tolerance in transplantation. 
C
ha
pt
er
 2
20
INTRODUCTION
Without immunosuppression, transplanted organs are rapidly rejected by the recipients immu-
ne system. The current immunosuppressive drugs, effectively reduce the immune response 
to alloantigens, resulting in a relatively low incidence of acute rejection. Most immunosup-
pressive drugs target the intracellular signals involved in T-cell activation following antigen 
presentation (1, 2) as shown in Figure 1. Conventional immunosuppressive drugs include 
corticosteroids, calcineurin inhibitors (CNI), IL-2 receptor-blocking antibodies, rapamycin and 
mycophenolate mofetil (MMF) . Characteristics of these drugs are summarized in Table 1. 
The long-term administration of immunosuppressants leads to many debilitating side effects 
influencing patient- and graft survival (3). Therefore, it is essential to minimize the use of im-
munosuppression. To accomplish this, alternative therapeutic strategies to induce and main-
tain transplant tolerance have to be developed. A possible strategy that is now extensively 
investigated is the induction and maintenance of transplant tolerance by regulatory T cells 
(Treg), in particular the CD4+CD25+Foxp3+ Treg. As immunosuppressive drugs affect conven-
tional effector T cells (Teff), they may also affect Treg. This notion has raised concerns about 
the influence of immunosuppressive drugs on the induction and maintenance of transplant 
tolerance by Treg and sparked intensive research on this issue. 
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Figure 1. After organ transplantation, the allo-activation of T cells can be suppressed using different immunosuppressive 
drugs. These drugs intervene with different signaling pathways involved in T-cell activation and proliferation, e.g. by interac-
tion with the IL-2 pathway. Differential effects of immunosuppressive drugs on regulatory T cells (Treg) and effector T cells 
(Teff) may be explained by differences in signal transduction pathways. For example  IL-2 does not primarily activate PI3K 
in Treg as in Teff. 
TCR/
 CD3
CD28
IL-2
IL2R
Gene transcription (IL-2)
PI3K ZAP70 CaN
NFkB MAPK NFAT
Cell Cycle
SGI
M G2
mTOR
PI3K
T cell
There is now convincing evidence that activation of Treg is governed by distinct signaling pa-
thways as compared to Teff. These differences may explain how immunosuppressants have 
distinct effects on Treg. In the following paragraphs we will discuss experimental as well as 
clinical studies that investigated the impact of immunosuppression on the development, pro-
liferation, survival and function of Treg, and how this may affect tolerance after organ trans-
plantation.
Distinct signaling pathways in Treg and Teff
To understand the differential effects of immunosuppression on Treg it is important to know 
what distinguishes these cells from Teff. It has been established that the X chromosome-enco-
ded transcription factor Foxp3 is highly expressed by Treg and essential for their development 
in the thymus. Furthermore, transgenic Foxp3 can convey suppressive function to naïve T 
cells (4, 5). Though Foxp3 possitivity can be observed in activated human Teff, this expres-
sion is transient and does not seem to induce a Treg phenotype (6). Mutations in the Foxp3 
gene in humans and mice results in an aggressive multi-organ autoimmune disease (7, 8). 
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Drug Mechanism of action Specific effects on 
effector T cells
Specific effects on 
regulatory T cells
Corticosteroids Cytosolic receptors,
Heat shock proteins, 
interfere with 
transcription factors
Induces apoptosis, 
Inhibit cytokine 
production, interfere with 
migration
Stimulate Foxp3 
expression, preserve 
suppressive activity and 
cell survival
Tacrolimus (FK506) Binds FKBP-12
Inhibits calcineurin
Inhibits cytokine production, 
inhibits T-cell activation and 
proliferation
Inhibit Foxp3 
expression and possible 
suppressor function
Cyclosporin A (CsA) Binds cyclophilins 
Inhibits calcineurin
Inhibits cytokine production, 
inhibits T-cell activation and 
proliferation
Inhibit Foxp3 
expression and possible 
suppressor function
CD25 mAbs 
(daclizumab/ basiliximab)
Binds CD25 as target 
epitope
Inhibits IL-2 dependent 
proliferation
Insufficient data
Rapamycin and derivates 
(sirolimus & everolimus)
Binds FKBP-12
Inhibits mammalian 
target of rapamycin 
(mTOR) 
Blocks p70 S6 kinase
Blocks T-cell proliferation Does not appear to 
effect survival and 
suppressor function
Mycophenolate mofetil 
(MMF)
Inosine monophosphate 
dehydrogenase inhibitor 
(with high affinity for 
type 2)
Selective blockade of 
lymphocyte proliferation
Does not appear to 
effect survival and sup-
pressor function
Table 1. Immunosuppressive drugs and their effect on T(reg) cells.
Recent transcriptional profiling studies of mouse Treg showed that at least 700 genes are up 
or down regulated by Foxp3 (9, 10). The IL-2 receptor α-chain (CD25) is one of the upregula-
ted genes, which results in the characteristic high expression of CD25 on Treg. Genes that are 
downregulated by Foxp3 include IL-2 and T-cell receptor (TCR) signaling molecules Zap70 
and ITK. Indeed, it has been shown that Foxp3+ Treg and Teff have a distinct response to 
TCR triggering (11, 12) e.g., Treg isolated from human or mice do not proliferate in vitro upon 
appropriate activation nor produce IL-2, IL-4 and Interferon (IFN)-γ cytokines (11). Moreover, 
signaling pathways involved in reorganization of the actin cytoskeleton (e.g. VAV), which is 
important for sustained signaling by the TCR, are shutdown in Treg (13). As a consequence of 
the suppression of IL-2 production in Treg, their development and survival strongly depends 
on the presence of exogenous IL-2 (14, 15).
It has been suggested that specifically in Treg, Foxp3 inhibits expression of IL-2 and other ge-
nes by interfering with transcriptional activation of Nuclear Factor of Activated T cells (NFAT). 
Indeed, in vitro experiments revealed that genes that were activated upon stimulation of Foxp3 
negative cells and suppressed in Foxp3 positive cells were activated in a calcineurin depen-
dent manner (i.e. inhibited by CNI) (9). This is consistent with the notion that NFAT is involved 
in the activation of these genes. Therefore, CNI may profoundly affect Treg cell programming 
by direct interference with NFAT:Foxp3 interactions (16, 17).
Another relevant difference in signal transduction between Treg and Teff is the finding that 
IL-2 primarily activates JAK/STAT signaling in Treg rather than the PhosphoInositide 3-Kinase 
(PI3K) signaling pathway (18-20). Interestingly, activation of the signaling pathway leading 
from PI3K to mammalian target of rapamycin (mTOR) was almost completely absent in both 
primary Treg and Foxp3-transgenic CD4+ T cells upon IL-2 receptor signaling (11). As some 
immunosuppressants interfere with IL-2 signaling in Teff, they will not prevent PI3K-signaling 
in Treg. 
Effects of immunosuppressive drugs on Treg: Experimental evidence
The possibility to culture and expand (alloantigen-specific) Treg (21-27), has opened up the 
possibility to study the effect of immunosuppressive drugs on these cells in vitro. Although not 
all CD4+CD25+Foxp3+ Treg have the same origin, they may all be important in transplantation 
tolerance. Most experiments with Treg and immunosuppressive medication focused on the 
natural occurring Treg, which is generated in the thymus. The adaptive or inducible Treg are 
thought to be either continuously generated from responding memory Teff in the periphery or 
to originate directly from the thymus with an naïve phenotype (CD45RA+) (28, 29). 
Corticosteroids
Corticoteroids are pleiotropic hormones that are used for their potent anti-inflammatory and 
immunomodulatory action. The most commonly used corticosteroids in transplantation are 
prednisone, prednisolone and methylprednisolone. Corticoteroids inhibit the action of trans-
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cription factors, like NF-κB and AP-1 that are involved in transcription of many cytokine and 
chemokine genes including IL-2, TNF-α and IFN-γ. It is known that CD4+CD25+Foxp3+ T cells 
highly express the glucocorticoid receptor as well as glucocorticoid-induced TNF receptor 
(GITR), a potent T-cell co-stimulatory receptor and regulator of Treg function (30). The activity 
of GITR has been implicated in peripheral tolerance since inhibition or a deficiency of GITR 
increases T-cell proliferation by abrogating the suppressive function of Treg (31-34). The first 
direct evidence that steroids affect Treg came from the observation that the female sex hor-
mone, estrogen, upregulates Foxp3 expression in mice, both in vitro and in vivo (35). Similar 
results were reported for the synthetic corticosteroid, dexamethasone, which induced Foxp3 
expression in short and long-term T-cell cultures, while preserving the suppressive capacity of 
Treg (36, 37). Furthermore, CD4+CD25+ T cells seemed resistant to dexamethasone-induced 
T-cell apoptosis (30). In mice, short-term simultaneous administration of dexamethasone and 
IL-2 expanded Foxp3+ Treg in peripheral lymphoid tissues (38). This treatment improved the 
suppressive capacity of splenic Treg in such a way that they were able to prevent the onset of 
autoimmune disease. Taken together, experimental evidence does not indicate that corticos-
teroids have a negative impact on Treg but rather improve the survival and function of Treg. 
One could even speculate whether this effect on Treg may account for some of the anti-inflam-
matory and immunosuppressive efficacy of steroids.
Calcineurin inhibitors
The CNI, Cyclosporin A (CsA) and Tacrolimus (Tacro), are potent inhibitors of the phospha-
tase calcineurin, which is essential for T-cell activation. By inhibiting calcineurin these drugs 
suppress the production of IL-2 and related cytokines through prevention of downstream acti-
vation of the transcription factor, NFAT. As discussed earlier, NFAT cooperates with Foxp3 to 
control Treg activation (17, 39). There are a few in vitro studies describing the effect of CNI on 
Treg. Baan et al. showed that in a Mixed Leukocyte Reaction (MLR) the induction of Foxp3 
mRNA was inhibited by both Tacro and CsA (40). This was confirmed by other studies which 
observed decreased Foxp3 mRNA and protein (41, 42) and a loss of the highly suppressive 
CD27+ Treg subset in cultures containing CsA (43). These later studies report contradicting 
effects of CsA on the suppressive function of Treg, one observing no effect with human Treg 
(43) and the other finding less suppression with mouse Treg (41). 
There are now recent in vivo data that show a negative effect of CNI on Treg. Treatment of 
mice with CsA compromised not only the thymic generation of Treg but also resulted in a 
sharp reduction of Treg in peripheral immune compartments (44). In a mouse bone marrow 
transplantation model, CsA administration inhibited Treg mediated suppression which was 
associated with reduced IL-2 production (41). Exogenous IL-2 was shown to overturn the 
reduced suppressive function of Treg by CsA. Together, these data suggest that CNI are not 
beneficial for Treg, but rather seem detrimental to survival and function of these cell. This 
further underlines the importance of IL-2 for Treg homeostasis.
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IL-2 Receptor-blocking antibodies
The chimeric monoclonal antibody (mAb) basiliximab and humanized mAb daclizumab are 
therapeutic antibodies directed against the α-chain of the IL-2 receptor (CD25). They directly 
interfere with receptor signaling by inhibiting the association and subsequent phosphorylation 
of the IL-2 receptor beta- and gamma-chains, induced by binding of IL-2. Few in vitro studies 
investigated the effect of CD25 mAb on Treg. One study showed inhibition of Foxp3 mRNA 
induction by CD25 mAb daclizumab in allostimulated PBMC (40) and another study showed 
downregulated Foxp3 staining after culture with daclizumab (45). However, in direct co-in-
cubations of Treg and Teff, CD25 antibodies did not interfere in the suppressive activities of 
CD4+CD25+ Treg (46). One recent study in mice did observe that particular CD25 antibodies 
reduced the percentage of Foxp3+ T cells within the CD4 fraction in vivo (47), whereas one 
earlier study suggest that anti-CD25 treatment does not reduce or deplete Treg but rather 
inactivate their suppressive function (48). Despite the convincing evidence that IL-2 is critical 
for Treg survival and function, no firm conclusions can be drawn from present studies on the 
effect of CD25 neutralizing antibodies on these cells.
Rapamycin
Rapamycin-derivatives, sirolimus and everolimus, are potent inhibitors of the IL-2 signaling 
pathway. They exert their effect at the level of mTOR, thereby preventing the transgression 
from G1 to S-phase (49). There are many studies that have investigated the impact of rapa-
mycin on Treg. Initial in vitro studies did not observe an effect of rapamycin on Foxp3 expres-
sion during allogenic stimulation, both for human (40) and mouse (41). This latter study also 
showed no effect of rapamycin on the suppressive capacity of Treg. Indeed two other studies 
confirmed that rapamycin does not interfere with the suppressive activity of CD4+CD25+ Treg 
on allogenic or polyclonal stimulated Teff (43, 46). In this setting, CD4+CD25+ Treg appeared 
more resistant to the pro-apoptotic effect of rapamycin than CD25- T cells (46). This obser-
vation was confirmed by culture experiments with rapamycin, were selective expansion of 
murine and human CD4+CD25+Foxp3+ Treg was observed, while at the same time killing or at 
least preventing expansion of Teff (43, 50-52). These differential effects of rapamycin on Treg 
and Teff seem paradoxical, given the critical dependency of Treg on IL-2 signals for survival. 
However, the fact that in Treg IL-2 primarily signals via the JAK/STAT pathway, rather than via 
the PI3K/mTOR pathway that is dominate in Teff, may help to explain these differences. 
Also in vivo, there is evidence that rapamycin treatment has favorable effects on Treg. In a 
study with mice by Battaglia et al. CD4+CD25+Foxp3+ Treg expanded ex vivo in the presence 
of rapamycin, prevented rejection of β-islet transplants in vivo (53). Furthermore, a recent 
study showed that rapamycin induces de novo expression of Foxp3 in murine alloantigen spe-
cific T cells dose dependently which appeared to be TGF-β1 dependent (42). Since rapamycin 
can induce the expression of TGF-β1, this may be an important mechanism contributing to the 
development of antigen-specific Treg (54). Interestingly a recent study suggests that rapamy-
cin can induce regulatory functions in conventional CD4+ T cells in culture (55). Furthermore, 
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evidence suggests that rapamycin conditioned dendritic cells are poor stimulators of allogenic 
T cells, but enrich for antigen specific Treg that can prolong cardiac graft survival in mice (56). 
In conclusion, there is substantial evidence that rapamycin favors Treg survival and function 
and, by suppressing Teff cells, tipping the balance from an aggressive towards a more protec-
tive type of alloimmune response. 
Mycophenolate mofetil 
MMF is a pro-drug of mycophenolic acid (MPA), an inhibitor of inosine monophosphate de-
hydrogenase. This is the rate-limiting enzyme in de novo synthesis of guanosine nucleotides 
and T cells in particular are dependent on this pathway for cell division. MMF suppresses T-
lymphocytic responses to allogeneic cells and other antigens (57). MMF has been shown to 
decrease the expression of CD25 on stimulated T cells in a dose dependent fashion (58, 59). 
There is only one study that specifically described the effect of MMF on Treg in vitro (41). MPA 
did not alter the expression of Foxp3 or affect the suppressive capacity of Treg. Therefore 
Treg may still be capable to function normally in the presence of MMF. Unpublished results 
from our laboratory support this, since MMF did not alter Treg function and their expression 
of Foxp3 in MLR. 
Effects of immunosuppressive drugs on Treg: The clinical evidence
As discussed in previous paragraphs, there is evidence that some of the most widely used 
immunosuppressive drugs in contemporary transplantation medicine have clear and distinct 
effects on the survival and function of CD4+CD25+Foxp3+ Treg. These effects are now suppor-
ted by the knowledge that Treg differ in their TCR and cytokine signaling response from Teff. 
However, what remains to be demonstrated is how immunosuppression affects the balance 
between immunoreactive and immunoregulatory cells in transplant recipients. In vitro studies 
and experimental transplant models showed that immunosuppression can affect Treg by in-
terfering with their function, survival and expansion. In the next paragraphs we will review the 
literature on Treg homeostasis and allosuppressive activity in the clinical setting and discuss 
the limitation of our current knowledge.
There is a general observation that the percentage of circulating CD4+CD25+ and CD4+Foxp3+ 
cells drops significantly in the months and years following transplantation (60, 61). Not only 
peripheral blood levels of Treg are reduced, as indicated in a recent study, also lower Foxp3 
mRNA and positive T cells were found in non-inflammed colon tissue from liver transplant 
recipients on triple therapy compared to healthy controls (62). These effects cannot only be 
attributed to the effect of immunosuppression, since many clinical parameters change after 
transplantation as well. However, the observation that operationally tolerant liver transplant 
recipients display a significantly increased proportion of CD4+CD25high cells compared to re-
cipients on immunosuppression, may support this suggestion (63, 64). On the contrary, the 
increased Treg proportions may also reflect the operational tolerant state of these patients 
and not result from the absence of immunosuppression.
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One of the first clinical studies that addressed the effect of specific immunosuppressive drugs 
on Treg was done by Salama et al., identifying CD4+CD25+ Treg from kidney transplant reci-
pients that can suppress alloantigen-specific responses (65). Despite induction therapy with 
an anti-IL-2 receptor antibody, CD4+CD25+ Treg could still be generated, suggesting no long-
term effect of anti-IL-2 receptor antibody on Treg induction. Also, more recent studies suggest 
that anti-IL-2 receptor antibody treatment does not affect the number or function of Treg in 
renal transplant recipients (45). During the first three months after transplantation, when the 
level of antibody is still high, a decreased percentage of CD4+CD25+Foxp3+ cells was ob-
served without an equivalent increase in CD4+Foxp3+ cells. In contrast, in liver transplantation 
recipients the CD4+Foxp3+ T-cell fraction was not affected after conversion from CNI mono-
therapy to MMF with a single dose of daclizumab, while expression of CD25 was significantly 
decreased (66). These differences may be due to the early intensive immunosuppressive 
treatment following kidney Tx (quadruple treatment) versus the relative low immunosuppres-
sion in liver Tx (monotherapy). Hence, the effect of combination therapies, frequently applied 
in the clinic, on the development of tolerance should be explored.
CNI versus rapamycine or MMF
Also in the clinical setting there is some evidence that IL-2 is a critical regulator of the home-
ostasis of Treg. In cancer patients treated with exogenous recombinant IL-2, the frequency of 
CD4+Foxp3+ Treg increases during therapy (67, 68). Now several retrospective studies compa-
red patients receiving CNI-based immunosuppression with those receiving rapamycin or MMF. 
In a study by Segundo et al., kidney transplant patients receiving CNI maintenance treatment 
had a significantly lower percentage of peripheral blood CD4+CD25+ and CD4+CD25high T cells 
compared to patients receiving rapamycin. Functionally, CD4+CD25+ cells from rapamycin tre-
ated recipients were shown to suppress the direct immune response, but were not compared 
to Treg from CNI treated recipients (69). Although in this study the percentage of CD4+Foxp3+ 
cells was not shown, these findings may suggest a shifted balance between immune reactive 
and regulatory cells by either CNI or rapamycin. Notwithstanding that, CD4+CD25+ cells from 
CNI treated kidney transplant patients have suppressive capacities (70).
Following Campath-1H induction therapy sirolimus treated recipients had higher proportions 
of CD4+CD25high cells compared to patients on CsA (71), confirming the findings of Segundo et 
al. The increased proportions reported by Noris et al., however, seem overstated, as CD25 ex-
pression on all CD4+ cells is increased and the determination of CD25 high, intermediate and 
low positive cells by subjective gating differed between CsA and sirolimus treated recipients. 
In vitro depletion of CD4+CD25high cells showed an increase in IFN-γ production by T cells of 
sirolimus-treated recipients while no changes were seen in the CsA group. This suggests ac-
tive regulation by Treg in the sirolimus group whereas the IFN-γ production by Teff from CsA 
treated recipients remained unchanged. Whether the increased proportion of CD4+CD25high 
T cells in rapamycin treated recipients contributes to a more tolerogenic immune response 
towards the graft remains to be determined.
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In lung transplantation, in contrast to the above mentioned studies, Meloni et al reported that 
the absolute number of CD4+CD25bright Treg, rather then the percentage of Treg within the T-
cell fraction, was not affected by CNI therapy (72). In stable MMF treated kidney transplant 
patients the measured donor-specific non-responsiveness was mediated by CD4+CD25+ cells 
(73). However, we have to be aware that almost all transplant patients included in these 
studies were on double or triple immunosuppression therapy, including corticosteroids in all 
patients, which complicates the interpretation of their data. 
Conclusion: Does in vitro evidence translate to the clinical setting?
Increasing evidence show that immunosuppressive drugs have a differential effect on Teff and 
Treg. In this context, several immunosuppressive agents have an effect on the number and/or 
function of Treg. Furthermore, experimental data suggest that the use of specific immuno-
suppression can be an essential component of strategies to induce and maintain transplant 
tolerance by Treg. Indeed, the few results from clinical studies support the distinct effects of 
various immunosuppressive regimens on Treg, but so far the consequence on clinical tole-
rance remains unknown. Therefore, the effects of immunosuppressive drugs on Teff and Treg 
should be further analyzed to extent the limited knowledge we have now. 
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Part II 
Regulatory T cells in peripheral blood

Chapter 3
Decrease of CD4+CD25+ T cells in peripheral blood 
after liver transplantation: association with immunosuppression
Ahmet Demirkiran, Alice Kok, Jaap Kwekkeboom, Herold J. Metselaar, 
Hugo W. Tilanus and Luc J.W. van der Laan
Transplantation Proceedings, 2005, 37, 1194–1196
ABSTRACT
CD25 (IL-2 receptor α-chain) marks a population of CD4 positive T cells with a suppressor phe-
notype. These CD4+CD25+ regulatory T cells can suppress both effector T cells and antigen-pre-
senting cells and have been identified as a principle regulator of tolerance in experimental trans-
plantation models. In the setting of human liver transplantation, however, little is known about the 
dynamics of these cells in relation to rejection, tolerance and immunosuppression. In the current 
study we determined CD4+CD25+ T cell in blood of liver transplant recipients using  flow cytome-
try and investigated a possible link with immunosuppressive therapy. Peripheral blood mononu-
clear cells (PBMC) of 27 liver transplant patients (pre-and 12 months post-transplantation) and 
16 healthy controls included. We found that the percentages of CD25+ cells within the CD4+ T-cell 
population was significantly reduced in patients at one year after transplantation. Also the total 
percentage of CD4 positive T cells declined significantly within this period, making the absolute re-
duction of regulatory T cells after transplantation even more profound. Comparing PBMC samples 
of patients and healthy controls revealed an increased percentage of CD4+ T cells in the patients 
before transplantation, probably related to the chronic liver illness. The reduction in CD4+CD25+ T 
cells after transplantation was similar for different immunosuppression regimens. All patients, ho-
wever, received calcineurin inhibitors suggesting a possible suppressive effect of this therapy on 
regulatory T cell levels in peripheral blood. Currently, assays for regulatory T cell activity are used 
to further support this hypothesis.
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INTRODUCTION
The IL-2 receptor α chain, CD25, which is expressed on T cells signals proliferation, differentiation, 
and survival upon ligation with IL-2. Furthermore, extensive evidence suggests that CD25 marks 
a population of CD4+ regulatory T cells co-expressing Foxp3, CTLA4 and GITR (1-4). These CD4+ 
CD25+ regulatory T cells have been shown to be critically involved in experimental models for 
transplantation tolerance by actively suppressing the allo-reactive T cell response (5-7). Even 
though CD4+CD25+ regulatory T cells have been identified in humans, so far no data have been 
published on the dynamics and function of these cells in the context of liver transplantation and 
the role of immunosuppressive medication herein. In the current study we determined the levels 
of CD4+CD25+ T cells in peripheral blood of liver transplant recipients and a possible link with im-
munosuppressive regimens was investigated.
MATERIALS AND METHODS
After receiving an appropriate informed consent, peripheral blood was obtained from 27 liver trans-
plant recipients within a month prior to and 12 months after liver transplantation. The induction 
therapy of immunosuppressive medication included cyclosporine A (CsA) or tacrolimus (TAC) and 
prednisolon, with some patients (n= 15) receiving IL-2 receptor blocking antibody (Basiliximab). 
The maintenance therapy consisted of CsA or TAC with or without prednisolon (Pred). Control 
peripheral blood samples were obtained from 16 healthy volunteers. Peripheral Blood Mononu-
clear Cells (PBMC) were isolated from heparinized blood by density gradient centrifugation using 
Ficoll Paque Plus (Amersham Biosciences, Upsala, Sweden). Monoclonal antibodies (Abs) used 
for flow cytometric analysis were: anti-CD4 PerCp-Cy5.5 (SK3) and -CD25 FITC (2A3), isotype 
controls IgG-1 PE and IgG-2A FITC Abs, all from Becton Dickinson (BD, San Jose, USA) and anti-
CD3-PE (UCTH1) Ab from Immunotech (Marseille, France). After thawing, PBMC were washed 
twice with PBS containing 0.5% BSA. Cells were incubated for 30 minutes at 4˚ C with conjugated 
Abs, washed two times and fixed with 2% paraformaldehyde before flowcytometric analysis on the 
FACS Calibur  (BD, Erembodegem, Belgium). All statistical analyses were performed using SPSS 
Inc. software (Chicago, USA). Significant differences were tested using either the Mann-Whitney 
U test or the Wilcoxon paired test.
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RESULTS AND DISCUSSION
Before examining the percentage of CD25 positive CD4 T cells, the fraction of CD4 positive T hel-
per cells within the total T cell population in peripheral blood was determined. As shown in Figure 
1A, the percentage of CD4+ cells of total CD3+  lymphocytes was found to be elevated (p= 0.015) 
in patients waiting to receive a liver transplant (average 67.5 ± 3.9 SEM) as compared to healthy 
controls (56.0 ± 2.6 SEM). This increased percentage of CD4+ T cells may be due to the chronic 
liver illness. When PBMC samples were examined one year post-transplantation, a significant 
decrease of the CD4+ T cell frequency was found (average 67.5 vs 50.2, p=0.002).
Next we looked at the percentage of CD25+ T cells within the CD4+ population. There was no 
significant difference in the percentage of CD4+CD25+ T cells between transplantation patients 
and healthy controls (not shown). However, in patients a significant reduction of the CD4+CD25+ T 
cell frequency was observed one year after transplantation (Figure 1B). The drop in CD25 positive 
cells was observed in more than two-third of all patients. Also a reduction in expression of CTLA4, 
an additional marker expressed on CD25+ regulatory T cells, was observed after transplantation. 
Furthermore, using a T cell proliferation assay we confirmed that CD4+CD25+ T cells from pa-
tients (both pre- and post-transplantation) are hyporesponsive and can suppress the response of 
CD4+CD25- T cells in a dose dependent manner (data not shown).
The reduction in CD4+ T cells, and the even further reduction of CD25 positive cells within this 
T cell fraction, could be a consequence of immunosuppressive medication. Therefore, different 
induction and maintenance therapies were compared. As shown in Figure 1C, patients receiving 
anti-IL2 receptor antibody, Basiliximab, had a similar reduction of CD4+CD25+ cells as compared 
to patients without Basiliximab-treatment. Also, no significant differences were observed between 
patients with or without steroid treatment as maintenance therapy. It is important to note, howe-
ver, that all transplant patients received calcineurin inhibitors CsA or TAC. Calcineurin inhibitors 
selectively block the expression of the IL2 gene. Evidence suggests that regulatory T cells require 
low dose IL2 signals for their survival and function (8, 9). Our data suggest that immunosuppres-
sive therapies, in particular the use of calcineurin inhibitors, reduce the numbers of CD4+CD25+ 
regulatory T cells, at least in peripheral blood. This illustrates the dilemma of immunosuppression: 
preventing acute rejection by blocking the activation of effector T cells, but also inhibiting the deve-
lopment of donor-specific tolerance by suppressing regulatory T cells. 
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Figure 1C. Different immune suppressive regimens 
showed comparable reduction of CD4+CD25+ T 
cells. Shown is the mean percentage of decrease 
one year after transplantation.
Figure 1B. After liver transplantation CD4+CD25+ T 
cell frequency significantly reduces (p=0.01, shown 
are individual CD4+CD25+ T cell frequencies). Bar 
indicates median.
Figure 1A. Percentage of CD4+ T cells in peripheral 
blood is increased before transplantation and decre-
ases significantly after transplantation (shown is the 
mean ± SEM).
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acute rejection in liver transplantation 
Ahmet Demirkiran, Alice Kok, Jaap Kwekkeboom, Johannes G. Kusters, 
Herold J. Metselaar, Hugo W. Tilanus, Luc J.W. van der Laan
Liver Transplantation, 2006, 12, 277-284
ABSTRACT 
Immune regulatory CD4+CD25+ T cells play a crucial role in inducing and maintaining allograft tole-
rance in experimental models of transplantation (Tx). In humans, the effect of Tx and immunosup-
pression on the function and homeostasis of CD4+CD25+ regulatory T cells (Treg) is not well cha-
racterized. In this study, the frequency of Treg in liver transplant recipients was determined based 
on flowcytometric analysis of CD4, CD25, CD45RO and CTLA-4 markers and the suppressor 
activity of Treg was assessed in a mixed-leukocyte-reaction. A link between Treg, acute rejection 
and immune suppressive treatment was investigated. Liver transplant recipients had significantly 
higher Treg levels in peripheral blood pre-Tx compared to healthy controls. After Tx, a significant 
drop in the Treg fraction was observed. This reduction of circulating Treg was transient and was 
associated with immunosuppression. In recipients who did not develop rejection, a relative reco-
very of Treg levels was seen within the first year after Tx. Recipients who experienced an episode 
of steroid-treated acute rejection, however, had sustained low Treg levels. The suppressive activity 
of CD4+CD25+ Treg from rejectors, non-rejectors and healthy controls on proliferation and IFN-γ 
production were indistinguishable. In conclusion, the percentage of CD4+CD25+CD45RO+CTLA-
4+ quadruple positive Treg in peripheral blood decrease significantly after liver Tx. Treatment with 
methylprednisolon during Tx and for acute rejection is associated with low circulating Treg. Des-
pite these quantitative differences between rejectors and non-rejectors, the suppressive quality of 
CD4+CD25+ Treg is identical in both groups.
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INTRODUCTION
Transplant tolerance, the ultimate goal in solid organ transplantation, occurs more often after 
transplantation (Tx) of the liver compared to other organs. Cessation of immune suppressive the-
rapy without allograft rejection has been reported to be successful in a considerable proportion of 
liver transplant recipients (1, 2). The exact mechanisms involved in achieving transplant tolerance 
remain unknown, although animal models suggest a possible role for regulatory T cells (Treg) (3, 
4). In vitro studies of a distinct subset of Treg expressing CD4, the α-chain of the IL-2 receptor 
(CD25) and the transcription factor Foxp3 showed that these cells do not proliferate upon stimula-
tion, but instead, suppress activation of effector T cells in a cell-contact dependent manner (5-7). 
Transfer of CD4+CD25+ Treg from animals with long-term surviving allografts to naïve recipients 
prevents the development of allograft rejection (8). The suppressive capacity of CD4+CD25+ Treg 
is not only restricted to foreign antigen-driven T-cell responses, but also entails auto-reactive T-
cell responses, thereby preventing the development of auto-immune diseases and maintaining 
peripheral tolerance to self-antigens (9, 10).
In vivo studies on the mechanism of Treg-mediated suppression have shown a functional role 
for cytotoxic T lymphocyte antigen 4 (CTLA4, CD152), which is constitutively expressed by 
CD4+CD25+ Treg (11, 12). Interestingly, the majority of suppressive CD4+CD25+ T cells are found 
in the memory T-cell population, characterized by the expression of CD45RO (13). Jonuleit et 
al have demonstrated that within the CD4+CD25+ fraction the CD45RO positive cells, and not 
the CD45RO negative cells, are anergic and have suppressive activity (14). These observations 
suggest that these cells have already encountered antigens and have acquired the phenotype of 
highly differentiated CD4+ T cells, distinguishing them from recently activated CD4+ T cells, which 
do not express CD45RO.
In the context of human liver Tx, the function and dynamics of Treg have not been extensively 
studied. The aim of this study was to reveal the effect of liver Tx and immune suppression on Treg 
in peripheral blood of liver transplant recipients. A relationship between the frequency of Treg and 
the development of acute rejection was investigated.
MATERIALS AND METHODS
Patients and healthy controls
After receiving an informed consent, heparinized peripheral blood was obtained from forty liver 
transplant recipients before and multiple time points after Tx. Ten patients developed acute rejec-
tion within three months after Tx and were treated with intravenous high doses of methylpredniso-
lon (Solumedrol, 3x1000mg). Acute rejection was confirmed by histological examination of liver 
biopsies using the Banff classification (1997). Rejection activity index of six or more defined rejec-
tion, as assessed by an experienced pathologist. Steroids (Prednison) were given to all patients 
starting with 100 mg per day and were weaned during the first six months after Tx. Some patients 
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remained on maintenance steroids (n=14). Blood samples obtained from sixteen healthy volun-
teers (6 males, 10 females) were used as control. The mean age of the controls was 31 years, 
not significantly different from the patient group. General characteristics and immune suppressive 
treatment of patients are summarized in Table 1.
Flow Cytometric Analysis
Mononuclear cells were obtained from heparinized blood by density gradient centrifugation over Fi-
coll-Paque plus (Amersham Biosciences, Buckinghamshire, UK). After isolation, cells were stored 
in 10% DMSO-containing medium at –180ºC. For flow cytometric analysis of Treg, the following 
fluorescent monoclonal antibodies were used: anti-CD4 (SK3)-PerCp-Cy5.5, -CD25 (2A3)-FITC, 
-CD45RO (UCHL-1)-APC purchased from BD Pharmingen (San Diego, CA). PE-conjugated anti-
CTLA-4 (BN13) was purchased from Immunotech (Marseille, France). Fluorescent mouse IgG-1 
and –2A (BD Pharmingen) antibodies were used as isotype controls. 
After thawing, cells were washed twice with phosphate-buffered saline (PBS) containing 0.3% 
bovine serum albumin (BSA) and incubated for 30 minutes with CD4, CD25 and CD45RO mAbs 
in PBS/0.3% BSA at 4ºC. Following primary incubation, cells were washed and for staining of 
intracellular CTLA-4, the cells were fixed and permeabilized using the IntraPrep Reagents (Immu-
notech, Marseille, France). Subsequently, the cells were washed and analysed by flowcytometry 
using FACS Calibur and CELLQuest Pro software (Becton Dickinson, San Jose, CA). The percen-
tage of Treg was calculated as quadruple positive cells (CD4+, CD25+, CD45RO+ and CTLA-4+) 
and expressed as a percentage of CD4 positive cells.
Mixed leukocyte reaction and IFN-γ production
RPMI 1640 medium with L-Glutamine (Bio Whittaker, Verviers, Belgium) supplemented with 10% 
pooled human serum (Dept. of Immunohematology and Bloodbank, Leiden University Medi-
cal Center, Leiden, The Netherlands), 100 μg/ml penicillin and 100 μg/ml streptomycin (Gibco, 
Paisley, UK) was used for T-cell culture. After isolation of PBMCs from fresh heparinized blood 
obtained one year after Tx CD4+ cells were purified using the untouched CD4+ T-cell isolation kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). After washing with PBS/0.3% BSA, CD4+ T cells 
were incubated with anti-CD25 microbeads (Miltenyi Biotec) followed by a positive selection of 
CD4+CD25+ T cells according to manufacturer’s instructions. The CD4+CD25- fraction was used 
as responder cells. The purified Treg fraction contained more than 90% pure CD4+CD25+ T cells. 
Donor or third-party allogeneic spleen cells were irradiated (5000 rads) and mixed (ratio 1:1) with 
CD4+CD25- responder T cells (5x104) in 96-well round-bottom plates. Suppression of proliferation 
was determined by adding increasing numbers (5 x 103, 1 x 104 or 1.5 x 104 cells) of CD4+CD25+ 
T cells to the mixed leukocyte reaction. At day 4 of culture, supernatants were collected and the 
concentration of IFN-γ was measured by ELISA (U-CyTech, Utrecht, The Netherlands). At day 
5, cultures were pulsed with 1 μCi per well of [3H] thymidine (Amersham, Little Chalfont, UK) for 
16 hours. Cells were harvested and proliferation was assessed by measuring radioactivity with a 
liquid scintillation counter. Cultures were performed in triplicate and the mean counts per minute 
were calculated. 
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Induction Therapy Maintenance Therapy
Patient Sex Age (y) 
at Tx
Disease IL-2R 
Blocker
Steroids 
(Prednison)
I.V. MP 
(500,g)
CNI Steroids 
(Prednison)
Acute 
Rejection
1 M 49 AC - + + Tac + +
2 M 40 AC - + + Tac - -
3 M 46 AC - + + CsA + -
4 M 45 AC - + + CsA - +
5 M 58 AC + + + Tac - +
6 F 56 AC + + + Tac - -
7 M 52 AC + + + Tac - -
8 F 54 AC - + + Tac + +
9 M 47 AC + + + Tac + -
10 M 61 AC + + + Tac - -
11 F 49 PBC - + + CsA + +
12 M 37 PSC + + + Tac + +
13 F 44 PSC - + + Tac + +
14 F 44 PBC - + + CsA - -
15 M 34 PSC - + + Tac - -
16 F 46 PBC + + + Tac - +
17 M 38 PSC + + + Tac - -
18 M 53 PBC + + + CsA + -
19 F 50 PSC + + + CsA + -
20 F 41 PBC + + + Tac - -
21 M 43 HBV - + + CsA - -
22 M 34 HBV - + + Tac - -
23 M 45 HBV + + + CsA - -
24 M 38 HBV + + + CsA - -
25 M 59 HBV + + + CsA - -
26 M 54 HBV + + + Tac - -
27 M 59 HCV + + + Tac - -
28 M 61 HCV - + + Tac + -
29 M 55 HBV - + + Tac + -
30 F 52 HBV - + + Tac - -
31 F 40 APUDoma - + + Tac + -
32 M 43 Wilson + + + CsA - -
33 M 59 AIH - + + Tac + -
34 F 40 CC + + + Tac - +
35 M 37 Byler + + + Tac - +
36 M 58 CC + + + Tac - -
37 M 35 PLD + + + Tac - -
38 M 49 CC + + + Tac - -
39 M 47 AIH + + + Tac + -
40 F 43 PLD + + + Tac - -
Tabel 1. Abbreviations: AC, alcoholic cirrhosis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; HBV, 
chronic hepatitis B virus infection; HCV, chronic hepatitis C virus infection; Wilson, Wilson’s disease; AIH, auto-immune 
hepatitis; CC, cryptogenic cirrhosis; Byler, Byler’s disease; PLD, polycystic liver disease. I.V. MP, intravenous methylpred-
nisolon; Tac, tacrolimus; CsA, cyclosporin A.
Statistical Analysis
Statistical analysis of the flowcytometry data was performed using software package SPSS ver-
sion 11.5 (SPSS, Chicago, IL). Significance was tested using the Mann-Whitney U test, the Wil-
coxon paired test and the Spearman’s two-tailed correlation test. P-values less than 0.05 were 
considered significant. For the MLR and IFN-γ  production, statistical analysis was performed by 
analysis of the logarithmic transformation of the dependent variable with random intercept and 
random slope using PROC Mixed in SAS version 8.2. (SAS Institute Inc, Cary, NC).
RESULTS
Increased  Treg in patients with end-stage liver disease 
Treg were identified in peripheral blood by flowcytometry based on the expression of CD4, CD25, 
CD45RO and intracellular CTLA-4. Hereafter quadruple positive cells (expressing CD4, CD25, 
CD45RO and CTLA-4) are referred to as Treg in the remainder of the manuscript. Representative 
dot plots of the flowcytometric analysis from a liver transplant recipient are shown in Figure 1A. 
Approximately 20% of the CD4+CD25+ cells express both CD45RO and CTLA-4, whereas 2% 
of the CD4+CD25- fraction was positive for these markers (not shown). The majority of CTLA-4 
expressing CD4+CD25+ cells had the memory phenotype (CD45RO+).
Figure 1A.  Assessment of Treg in peripheral blood of liver transplant patients and healthy controls on basis of CD4, CD25, 
CD45RO and CTLA-4 (CD152) co-expression. Representative dot plots are shown from a liver transplant patient. The right 
panels were gated on the CD4+CD25+ cells in the upper left plot. The majority of CD4+CD25+ cells have a memory pheno-
type (CD45RO+) and approximately 20% of these cells co-express CTLA4. 
C
ha
pt
er
 4
50
Patients with end-stage liver disease had significantly higher Treg percentages compared to he-
althy controls (Figure 1B). Highest levels were seen in patients with bile duct diseases and viral he-
patitis, whereas modest elevations were found in alcoholic cirrhosis and for other liver diseases.
Figure 1B. Elevated levels of Tregs in patients with end-stage liver disease. The percentage of Tregs is calculated as 
quadruple positive cells (CD4+, CD25+, CD45RO+ and CTLA-4+) and expressed as the percentage of CD4 positive cells. 
Patients with chronic liver disease (CLD) had increased Tregs in peripheral blood compared to healthy controls (HC, 
**p<0.001).  Treg levels in the four main types of CLD were all significantly different from healthy controls, with highest levels 
of Tregs in bile duct diseases and viral hepatitis (* p< 0.05). Shown is the mean ±SEM.
Decrease of  Treg after liver transplantation 
Recently, we have shown that CD4+ and CD4+CD25+ T lymphocytes within the CD3+ population 
were significantly reduced in peripheral blood one year after liver Tx (15). Assessment of Treg, 
expressing CD4, CD25, CD45RO and CTLA-4, showed a similar reduction (Figure 2A). Lowest 
levels were observed at three months after Tx, followed by a relative increase at twelve months 
and at later time points. A significant correlation was found between Treg levels within the CD4+ 
population before and one year after Tx (Figure 2B, p<0.001). 
Figure 2A. Decrease of Treg in peripheral blood after liver transplantation. Shown are the mean percentages of 
CD4+CD25+CD45RO+CTLA-4+ cells within the CD4+ population of liver transplant recipients (n=40). At all post-Tx time 
points Tregs were significantly decreased (* pre vs. post, p<0.001). Treg decreased dramatically in the early months after 
liver Tx, but showed a relative increase at one year. ( B )  Pre-Tx Treg levels correlate significantly with levels one year Tx.
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Acute rejection is associated with reduced Treg levels
A link between the level of Treg and the occurrence of a rejection episode in the first three months 
after liver Tx was investigated. Figure 3A shows Treg levels for rejectors and non-rejectors. One 
year after Tx, a significantly lower percentage of Treg within the CD4+ T-cell population was ob-
served in patients who experienced an episode of acute rejection compared to patients who did 
not develop allograft rejection (p=0.005). In Figure 3B representative dot plots of the flowcytome-
tric analysis for a rejector and a non-rejector are shown. Within the CD4+CD25+ fraction, there was 
an increased proportion of CD45RO+CTLA-4+ cells in non-rejectors compared to rejectors treated 
with intravenous methylprednisolon. A link between Treg levels and acute rejection was confirmed 
in an univariate analysis (ANOVA, p=0.003). After the first year, Treg levels showed a relative 
increase in the rejection group (p<0.05), while remaining stable in non-rejectors. These results 
suggest a transient reduction of Treg with different kinetics between rejectors and non-rejectors.
Figure 3A. Acute rejection after Tx 
was associated with reduced Treg 
fractions. The mean percentages of 
CD4+CD25+CD45RO+CTLA-4+ cells 
(± SEM) are shown. Patients, who ex-
perienced an episode of (methylpred-
nisolon-treated) acute rejection (n=10) 
within three months after Tx, had sig-
nificantly lower Tregs one year after 
Tx compared to non-rejectors (n=30). 
No significant differences were seen at 
other time points. T= months after Tx. 
Figure 3B.  Representative dot plots 
are shown of CD45RO and CTLA-4 
expression within the gated popula-
tion of CD4+CD25+ cells for a rejector 
and a non-rejector at one year post-
Tx. Rejectors had significantly lower 
CD45RO+CTLA-4+ double positive 
CD4+CD25+ cells compared to non-re-
jectors. All gates were based on isotype 
matched control stainings.
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Figure 4.  Comparison of different immune suppressive regimens with the percentage decrease of Treg one year after 
Tx. All patients were on treatment  with a calcineurin inhibitor, either cyclosporin A (CsA, n=12) or tacrolimus (Tac, n=28). 
Steroids (Prednison) as additional maintenance therapy were applied to 14 of 40 patients. IL2-receptor blocker, Basiliximab, 
was given to 24 patients. Ten patients with acute rejection were treated with high doses of intravenous methylprednisolon 
(Solumedrol, 3 x 1000mg). Patients treated for acute rejection with methylprednisolon showed a more profound decrease of 
Treg (*p=0.005). Maintenance steroid treatment also showed a stronger decrease, but did not reach statistical significance. 
No difference was seen between CsA or Tac use, nor between patients receiving an IL2-receptor blocker and patients who 
did not.
Differential effects of immune suppressive regimens on Treg
To determine whether there was a correlation between immune suppressive regimens and Treg 
in peripheral blood, the relative reduction at one year post-Tx in relation to individual immune 
suppressants was assessed (Figure 4). All regimens included calcineurin inhibition, either cyclos-
porine A or FK506 (tacrolimus). Equal Treg reduction was observed in the cyclosporine or the 
tacrolimus groups at all time points after Tx. IL2-receptor blockade, Basiliximab, given as induction 
immune suppressive therapy, also had no impact on Treg fractions. Patients receiving steroids 
(Prednison) as maintenance therapy showed a trend towards a stronger decrease at one year. 
Both rejectors and non-rejectors received methylprednisolon (1 x 500mg) during Tx, which may 
explain the reduction of Treg seen in all patients at three months (Figure 3A). Additional treatment 
with methylprednisolon (3 x 1000mg) for acute rejection resulted in a significantly higher decrease 
compared to non-rejectors (Figure 4). 
Treg-mediated suppressive activity is not different between rejectors and non-rejectors
The suppressive activity of Treg one year after Tx was determined from rejectors and non-rejec-
tors in a mixed-leukocyte-reaction using donor and third-party allogeneic spleen cells. Recipient T 
cells showed a hyporesponsiveness against donor spleen cells compared to third party, even after 
depletion of CD4+CD25+ T cells (data not shown). Because of this low anti-donor response, further 
suppression of this response by regulatory CD4+CD25+ T cells could not be determined. Figure 5 
shows suppression of the third-party immune response. Suppression of proliferation (Figure 5A) 
and cytokine production (Figure 5B) of effector CD4+CD25- T cells from rejectors, non-rejectors 
and healthy controls was comparable on a cell-for-cell basis, indicating that the suppressive acti-
vity of Treg is not affected by continuous immune suppression. 
Regulatory T cells decrease after liver transplantation   53
Figure 5. Comparable suppressor activity by Treg from 
rejectors, non-rejectors and healthy controls. One year 
after Tx, CD4+CD25+ T-cell mediated suppression was 
determined in a mixed-leukocyte-reaction for patients 
who experienced acute rejection (n=3), patients who did 
not reject (n=3) and healthy controls (n=3). Irradiated 
third-party spleen cells (5x104) were used for stimulation 
and mixed with responder CD4+CD25- T cells (5x104). 
Subsequently, purified CD4+CD25+ T cells were added in 
increasing numbers: 5x103 (0.1), 1x104 (0.2) and 1.5x104 
(0.3). 
Figure 5A. CD4+CD25+ T cells inhibit the allogeneic T cell 
response mediated by CD4+CD25- T cells (p<0.001). Af-
ter 5 days of culture, T cell proliferation was determined. 
Relative proliferation was calculated with the means of 
triplicate determinations. In rejectors, non-rejectors and 
healthy controls inhibition of proliferation was similar (p= 
not significant).
Figure 5B. Treg inhibit IFN-γ production by effector 
CD4+CD25- T cells. Shown are the relative mean IFNγ 
concentrations for three individuals in each group, as de-
termined by ELISA.
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DISCUSSION
The role of Treg in experimental models of transplant tolerance is well established. In the current 
study we found that after human liver Tx the percentage of Treg expressing CD4, CD25, CD45RO 
and CTLA-4, changes dramatically. Levels of these Treg in peripheral blood significantly decre-
ased after Tx. In a previous study we found that also the total CD4+ fraction within the T cell popu-
lation was reduced in the first year after Tx (15). Taken this finding into consideration, the absolute 
reduction of Treg  was even more profound than shown in Figure 2A. Significant differences in 
Treg levels were found between patients who experienced acute rejection versus non-rejectors 
(Figure 3A). Accordingly, acute rejection was associated with significantly lower Foxp3 mRNA le-
vels one year after Tx (data not shown). Despite the quantitative changes, the suppressive activity 
of isolated CD4+CD25+ T cells from liver transplant recipients, both rejectors and non-rejectors, 
was comparable to that of healthy controls (Figure 5). On a cell-for-cell basis the inhibition of T-
cell proliferation and IFN-γ production upon allogeneic stimulation was similar for rejectors and 
non-rejectors, however the levels of Treg in blood were three times lower in rejectors (Figure 3A) 
indicating a higher overall suppression in non-rejectors.
The direct T-cell response to donor antigens after Tx, as determined by a mixed-leukocyte reac-
tion, was low or undetectable in most recipients. There are a number of non-mutually exclusive 
mechanisms that can be responsible for this state of donor-specific hyporesponsiveness. These 
mechanisms include T cell anergy, mixed chimerism, deletion of reactive T cells or active immune 
regulation by donor specific Treg. The hyporesponsiveness is more frequent in liver Tx compared 
to heart Tx (16). In our experience, depletion of CD4+CD25+ cells did not overcome the hypores-
ponsiveness in the mixed-leukocyte reaction (data not shown), suggesting that other CD25- Treg 
populations (17, 18) or other mechanisms than immune regulation might be in play. To be able to 
determine the suppressive capacity of Treg after Tx, we used third-party cells as stimulus in the 
mixed-leukocyte reaction. It is well established that the response to unrelated, third-party, allo-an-
tigens is maintained after Tx. This way we were able to demonstrate that the suppressive activity 
of CD4+CD25+ regulatory T cells was maintained after Tx and comparable between rejectors and 
non-rejectors (Figure 5). This, however, does not exclude a possible role for other significant regu-
latory populations, like CD8+CD28- suppressor T cells, in clinical transplant tolerance (19-21).
The quantitative changes seen in Treg after Tx might be a result of immune suppressive therapy. 
A recent study showed reduced levels of CD4+CD25high cells in immune suppressed liver Tx re-
cipients compared to recipients who were free of immune suppression (22). All patients in our 
study were treated with calcineurin inhibitors (cyclosporin A or tacrolimus). Calcineurin inhibitors 
are potent inhibitors of T-cell activation by blocking IL-2 production. As IL-2 is essential for Treg 
function and survival (23), blocking IL-2 production by calcineurin inhibitors may thereby negati-
vely effect the Treg homeostasis and therefore hamper tolerance induction (24-29). In addition, 
a recent study by Baan et al. showed reduced induction of Foxp3 in the presence of calcineurin 
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inhibitors (both cyclosporin A and tacrolimus) in the MLR (30). On the other hand, in our study 
group treatment with anti-IL-2 receptor antibody (Basiliximab) had no clear effect on Treg levels at 
three months or one year after Tx (Figure 5).
In the first three months after Tx the intensive immune suppressive treatment directly following 
Tx may have caused the strong drop in Treg percentages. All patients received methylpredniso-
lon (Solumedrol) and high doses of steroids (Prednison). It is well known that steroids like me-
thylprednisolon induce apoptosis of lymphocytes. Apoptosis of Treg could explain the significant 
reduction of circulating Treg in the first months after transplantation and the sustained reduction 
in methylprednisolon-treated rejectors. At later time points after Tx (1-4 years), the percentage of 
Treg showed a relative increase in patients who were free of acute rejection suggesting that the 
reduction of Treg is transient. In patients who experienced an episode of rejection, however, Treg 
levels remained low throughout the first year and only showed a relative increase at two years 
or later. Additionally, patients receiving steroid maintenance therapy also showed reduced Treg 
levels after Tx (Figure 4), though this did not reach statistical significance due to small sample 
size. Taken together, these findings further support the negative and transient effect of steroid 
treatment on circulating Treg. This is consistent with an earlier report that methylprednisolon inhi-
bits spontaneous acceptance of the liver in a rat allo-Tx model, that might be linked to Treg (31). 
Moreover, in two other models of allograft tolerance methylprednisolon also inhibited acceptance 
of the transplanted organ (27, 32). 
Interestingly, patients with end-stage liver disease have an increased fraction of circulating Treg 
compared to healthy controls. Recent studies have shown that Hepatitis B and Hepatitis C virus 
infection is associated with an increase of Treg in peripheral blood (33, 34). Also in our study group 
patients with viral hepatitis had three times higher Treg levels than controls. Furthermore, we 
found that high pre-Tx Treg levels correlated with relatively high Treg levels post-Tx (Figure 2B). 
This correlation suggests that high levels of Treg, linked to the underlying disease, determine the 
level of Treg at one year post-Tx. Consistently, patients with viral hepatitis did not develop acute 
rejection (Table 1), a result that may involve the increased Treg levels seen in these patients. It is 
well documented that patients with hepatitis B infection have a lower incidence of acute rejection 
(35). On the contrary, patients with PBC or PSC also showed increased Treg, yet rejection was 
seen in four out of ten patients. This could be a consequence of an impaired Treg function as seen 
in some autoimmune diseases (36).  
Understanding the role of Treg in the immune response after allo-transplantation  may contribute 
to the identification of patients who acquired operational tolerance and therefore would not need 
immune suppressive treatment. Indeed, there is some evidence that pediatric patients who ac-
quired operational tolerance after liver Tx have increased Treg levels compared to patients on im-
munosuppression (22). Our  study demonstrates an association between the homeostasis of Treg 
after Tx and acute rejection, illustrating the current dilemma of immune suppressive treatment: 
C
ha
pt
er
 4
56
on the one hand preventing rejection, but on the other hand inhibiting Treg and thereby possibly 
interfering with the development of transplant tolerance.
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Chapter 5
Changes of circulating CD4+Foxp3+ regulatory T cells 
after conversion from calcineurin inhibitor to 
mycophenolate mofetil in liver transplantation
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Jaap Kwekkeboom, Hugo W. Tilanus, Herold J. Metselaar and Luc J.W. van der Laan
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ABSTRACT
CD4+Foxp3+ regulatory T cells (Treg) depend on IL-2 for their function and survival. By interfering 
with the IL-2 production, calcineurin inhibitors (CNI) may negatively effect Treg. Here, we des-
cribe the effects of conversion from CNI to mycophenolate mofetil (MMF) on renal function, Treg 
frequency and phenotype in liver transplant recipients. Patients (n=16) with renal impairment on 
CNI were converted to MMF and received a single dose of IL-2-receptor blocking antibody (Dacli-
zumab). Control patients (n=8) continued CNI treatment. Six months after conversion to MMF the 
percentage of CD4+Foxp3+ and CD4+CD25bright cells within CD3+ cells increased both by 2.2 fold. 
Foxp3 mRNA analysis of peripheral blood mononuclear cells confirmed the enrichment of Foxp3. 
CD25 expression on CD4+Foxp3+, but not Foxp3-, cells significantly increased at six months com-
pared to pre-conversion. Daclizumab treatment resulted in a 75 percent blocking of CD25 at one 
month, but this did not affect Treg levels. Renal function improved and acute rejection occurred 
in two patients (13%) after conversion. Conversion to MMF significantly improves renal function 
and increases the percentage and CD25 expression of circulating Treg. This shows that MMF 
therapy can overturn the repressive effect of CNI on circulating Treg and therefore may promote 
Treg mediated tolerance.
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INTRODUCTION
The checks and balances of immune reactive and immune suppressive cells likely determine 
whether there is immune reactivity to donor antigens or non-responsiveness (tolerance). Tole-
rance to self and foreign antigens involves the action of regulatory T cells (Treg) (1, 2). These 
T cells with suppressive capacities were first identified for their ability to prevent organ specific 
autoimmune diseases in mice (1). In experimental transplant models these cells can transfer tole-
rance to donor antigens (2). Recent studies suggest that calcineurin inhibitors (CNI, cyclosporin A 
or tacrolimus), belonging to current standard immunosuppressive therapy after organ transplan-
tation (Tx), interfere with the expansion, survival and possibly function of Treg in vitro (3, 4) and 
in vivo (5, 6). CNI are known as potent blockers of IL-2 production and it is established that IL-2 
is critically important for the survival of Treg (7). This could explain why CNI have been reported 
to be detrimental to both spontaneous experimental transplant tolerance in vivo and tolerance 
induced by co-stimulatory blockade (8, 9). The clinical use of CNI is associated with considerable 
non-immunological side effects, most importantly renal dysfunction due to nephrotoxicity (10) but 
also diabetes mellitus, hyperlipidemia and hypertension.
Clinical studies have shown that conversion of CNI to immunosuppressants like rapamycin or my-
cophenolate mofetil (MMF) can halt or even reverse CNI associated side effects. In liver Tx, CNI 
conversion to MMF based immune suppression in particular improved renal function but was also 
associated with a considerable risk of acute rejection (11, 12). Recent studies suggest that rapa-
mycin, unlike CNI, does not interfere with the survival and alloantigen-driven expansion of Treg in 
vitro (3, 4) and in vivo (6). There is now accumulating evidence that the inosine monophosphate 
inhibitor MMF, an IL-2 independent immunosuppressant, has similar effects on Treg as rapamycin. 
It was shown in different experimental transplant models that MMF does not interfere with Treg 
function and positively effect tolerance induction (5, 9, 13). 
The aim of the current study is to determine the effect of conversion from CNI to MMF monothe-
rapy on frequency and phenotype of circulating CD4+Foxp3+ Treg. To minimize the risk of con-
version-associated acute rejection recipients were treated with additional induction IL-2 receptor 
blockade. After conversion to MMF, a rapid improvement in renal function was observed as well 
as elevated percentages of circulating CD4+Foxp3+ Treg with increased IL-2 receptor alpha chain 
(CD25) expression. Possible implications in these changes with respect to transplant tolerance 
will be discussed.
PATIENTS AND METHODS
Patients and study design
Liver transplant recipients transplanted at the Erasmus MC (University Medical Center Rotter-
dam) on CNI maintenance monotherapy and at least 12 months after Tx, were screened for renal 
dysfunction. Renal dysfunction was defined based on increased serum creatinin and blood urea 
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nitrogen (BUN) levels and a calculated creatinin clearance less than 60 ml/min. To rule out other 
causes of renal dysfunction ultrasound of kidneys and aorta were performed. Only patients older 
than 18 years, who provided written informed consent, were consecutively enrolled. Exclusion 
criteria included abnormal graft function, active infection, malignancy, a history of severe (steroid-
resistant or repeated) rejection and other causes of renal dysfunction. 
Initially this was an open, randomized study comparing MMF-Daclizumab based regimen with 
standard CNI based drug regimen. At time-point zero one gift of 2 mg/kg bodyweight of Dacluzimab 
was given intravenously and oral MMF was started at a dose of 2 gram a day. CNI was stopped 
completely at the same day. MMF dose was not adapted to trough levels. After the study period 
the majority of the patients in the CNI group were also converted to the MMF-Daclizumab based 
regimen (Figure 1). The composite primary endpoint of this study was the improvement of renal 
function: decrease in serum creatinin, BUN and increase in creatinin clearance during the first 6 
months after randomization. Creatinin clearance was calculated with the Cockroft-Gault equation 
and in a subset of patients glomerular filtration rate (GFR) was measured. Secondary endpoints 
included biopsy proven rejection, allograft dysfunction, patient death at 6 months and graft loss 
at 6 months. During the follow up, liver and renal functions were assessed on regular basis in the 
outpatient clinic. When acute rejection was diagnosed intravenous methylprednisolon (Solumed-
rol, 3x1000mg) was administered together with re-introduction of CNI and discontinuation of MMF. 
Acute rejection was confirmed by histological examination of liver biopsies using the Banff classifi-
cation. General characteristics of the study group are summarized in Table 1. In the analysis, three 
patients were excluded: one in the control group due to deterioration of renal function requiring 
dialysis and three in the conversion group due to acute rejection (n=2) and allograft dysfunction 
without clear cause (n=1). For flow cytometric and RT-PCR analysis heparinized peripheral blood 
was obtained from all patients before and at multiple time points after randomization. 
Flow Cytometric Analysis
Peripheral Blood Mononuclear Cells (PBMC) were obtained by density gradient centrifugation over 
Ficoll-Paque plus (Amersham Biosciences, Buckinghamshire, UK) and stored frozen at –135ºC. 
After thawing, PBMC were washed twice with phosphate-buffered saline (PBS) containing 0.3% 
bovine serum albumin (BSA) followed by staining with primary monoclonal antibodies in PBS/
0.3%BSA (30 minutes at 4ºC). The following fluorochrome-conjugated monoclonal antibodies 
were used: CD25 (clone 2A3)-FITC, CD25 (clone M-A251)-PE, CD4-PerCP-Cy5.5 from Becton 
Dickinson (San Jose, USA), CTLA-4-APC, CD3-FITC and IgG2a-PE from Immunotech (Marseille, 
France), Foxp3-APC and isotype IgG2a-APC from eBiosciences (San Diego, USA). To determine 
the level of CD25 blockade by Daclizumab, we used two different clones of anti-CD25 antibody, 
which bind different epitopes. Antibody concentrations were titrated to obtain the same mean flu-
orescence intensity for both CD25 antibodies. In this manner the the extent of CD25 blocking by 
cell-bound Daclizumab was calculated. To define maximal receptor blocking, 5 x 106 PBMC were 
incubated with 25 µg/ml Daclizumab (30 minutes at 4ºC) in vitro prior to CD25 staining.
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Study patients 
(n=16)
Controls 
(n=8) p-value
Mean age ± SD (yrs) 60±11 66±5 NS
M:F 8:8 3:5 NS
Mean time after Tx (yrs) 9±4 7±2 NS
Indication LTx
Sclerosing Cholangitis 3 2 NS
Alcoholic Cirrhosis 2 2 NS
Cryptogeneic Cirrhosis 3 1 NS
Biliary Cirrhosis 3 1 NS
Viral Hepatitis 2 0 NS
Acute Liver Failure 3 1 NS
Haemangioendothelioma 0 1 NS
Maintenance Immunosuppression
Cyclosporin A monotherapy 11 5 NS
Tacrolimus monotherapy 5 3 NS
Following primary incubation cells were washed, and for staining of intracellular CTLA-4 or Foxp3, 
the cells were fixed and permeabilized using the IntraPrep Reagents (Immunotech, Marseille, 
France) or fixation/permeabilization agents supplied by eBiosciences, respectively. Analysis by 
flowcytometry was performed using FACS Calibur and CELLQuest Pro software (Becton Dickin-
son, San Jose, CA). The percentages of Treg were calculated as a percentage of total CD3+CD4+ 
T cells.
Quantitative RT-PCR
From PBMC (1 x 106 cells) erythrocytes were lysed with a buffer containing ammoniumchloride, 
sodium bicarbonate and EDTA by incubation for 7 min on ice. The remaining leukocyte fraction 
was pelleted and resuspended in 0.5 ml TRIzol reagent (Life Technologies, GmbH, Karlsruhe, 
Germany) at 4ºC. After homogenization, 20 µg poly A (Boehringer, Mannheim, Germany) was 
added and the TRIzol lysates were directly stored at -80ºC. Total RNA was extracted with 160 
μl of cold chloroform-isoamylalcohol and subsequently precipitated with ice-cold 80% ethanol 
(350 µl). The precipitated solution was then loaded on a RNA-isolation column from the Qiagen 
RNeasy isolation kit (Qiagen, Venlo, The Netherlands) and RNA was isolated according to the 
manufacturer’s instructions. Total RNA was denaturated for 10 min at 80°C and then chilled to 4°C. 
First-strand cDNA synthesis was performed as previously described (14). Real-time RT-PCR was 
used to quantify Foxp3 mRNA. The constant region of the T cell receptor α chain (TCR-Cα) RNA 
was quantified to use as reference gene. The primers and probes for Foxp3 were obtained from 
Assays-on-Demand Gene Expression Product and pre-developed Taqman PDAR assays (Ap-
plied Biosystems). Each Taqman probe was labeled at the 5´end with the reporter dye molecule 
6-carboxyfluorescein. 5 µl cDNA was added to 20 µl PCR mixture containing 12,5 µl Universal 
Table 1. Baseline patient characteristics
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PCR Master Mix (Applied Biosystems), 0.625 µl primer/probe mix and 6.875 µl H2O. The choice 
of primer and probe for the measurement of TCR-Cα transcripts was as previously described (14).
Amplifications were performed using the ABI 7700 sequence detector system (Applied Biosy-
stems) under the following conditions: a first step of 2-min 50°C and 10-min 95°C followed by 40 
cycles of 15 seconds at 95°C and 1 min at 60°C (for TCR-Cα 1 min at 58°C). The target message 
was quantified by measuring threshold cycle (Ct). Two negative controls (no template), and two 
positive reference samples were included for each determination. Samples negative for the TCR-
Cα genes were excluded from further analysis. The relative Foxp3 expression based on TCR-Cα 
was calculated using the comparative ΔΔCt formula: ΔΔCT (Ct Target – Ct TCR-Cα) sample - (Ct 
Target – Ct TCR-Cα) control. The fold change was calculated using 2 
–ΔΔCt.
Statistical Analysis
Statistical analysis was performed using SPSS Inc. software version 11.0 (Chicago, Ill, USA). 
Comparisons of clinical parameters and Treg levels were performed with Wilcoxon matched paired 
test or the Mann-Whitney test. P-value less than 0.05 was considered to be significant.
RESULTS
Clinical Outcomes
Eighteen patients fulfilled the entry criteria and were included for the study (Figure 1). 
As early as one month after conversion to MMF an improvement of renal function was observed. 
18  patients fulfilled inclusion
18  randomised
10 study patients 8 control patients 1 deterioration of renal function
7 analysed for 
primary endpoint
6 cross-over after 
study period
13 analysed for 
primary endpoint
2 acute rejection,
1 abnormal liver 
function
Figure 1. Study design
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Relative to baseline values, serum creatinin decreased with a mean of 16% ± 9% (SD) at six 
months after conversion (Figure 2A). BUN levels also significantly decreased (Figure 2B). In the 
control group serum creatinin and BUN remained unchanged. The calculated creatinin clearance 
increased significantly in the conversion group (p=0.001), while remaining stable in the control 
group (Table 2). In seven patients in the conversion group the GFR was measured and showed a 
significant increase at six months confirming the improvement of renal function (p=0.018), while 
no changes were seen in the control group (n=4; Table 2). Conversion patients at 6 months (n=13) 
had a significant lower serum bilirubin level (p=0.034), while this remained unchanged in control 
patients (n=7; Table 2). Furthermore, after conversion the systolic blood pressure was significantly 
lower (p=0.001, data not shown). In these patients also the diastolic pressure seemed lower, but 
this did not reached significance (p=0.08). Analysis of serum ALT, AST, AP and γGT and lipids 
showed no significant differences (data not shown).
Two cases of acute rejection occurred in the conversion group: one at one month and the other at 
six months after conversion. Rejection was confirmed with histologically and successfully treated 
with intravenous methylprednisolon and re-introduction of CNI.
Figure 2. Improved renal function after conversion from CNI to MMF monotherapy. ( A ) Serum creatinin levels were 
measured at baseline, one, three and six months after conversion (n=13). Significant decrease of serum creatinin levels 
was observed after conversion at all time points (*p<0.01). ( B ) BUN levels significantly decrease in the conversion group 
(*p<0.01), but remain unchanged in the control group (n=7). Shown are the means ± SD. Asterisks indicate statistical signi-
ficance in comparison to baseline.
Conversion patients Control patients
Baseline 6 months N Baseline 6 months N
Mean serum creatinin (μmol/L) 158±35 132±30 * 13 154±23 152±32 7
Mean serum BUN (mmol/L) 13±4 9±2 * 13 12±2 11±3 7
Creatinin Clearence (ml/min) 45±14 56±19 * 13 38±16 42±14 7
GFR (ml/min) 39±7 46±11 * 7 44±13 44±12 4
Serum Bilirubin 10±3 8±2 * 13 10±2 9±2 7
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Table 2. Clinical parameters at baseline and 6 months, * p< 0.05
A B
Increase of CD4+Foxp3+ T cells after conversion to MMF
To assess the effect of immunosuppression conversion on Treg, flowcytometric analysis of Foxp3 
expression on PBMC was performed. A representative dot plot of Foxp3 expression within the 
CD4+ T cells is shown in Figure 3A. The total proportion of Foxp3+ within the CD4+ T cells signifi-
cantly increased after conversion (Figure 3B). At six months after conversion the mean increase 
over baseline levels was 120% ± 37% SEM (p=0.008) and at 9/12 months 99% ± 33% SEM 
(p=0.015). No significant changes were seen in the control group. 
Figure 3. Increase in proportion of CD4+Foxp3+ T 
cells after conversion to MMF. ( A ) Representative 
dot plot showing Foxp3+ cells within the CD3+CD4+ 
T-cell population. ( B ) The proportions of Foxp3+ 
cells within the CD3+CD4+ T cells increased signi-
ficantly at six and nine to twelve months after con-
version (*p< 0.005 compared to baseline). 11 out of 
12 patients showed a more then 25% increase in 
Foxp3+ cells at 6 months. ( C ) In the control patients 
(n=7), who continued CNI, no significant differences 
were observed. 
RT-PCR analysis confirmed the increase of Foxp3+ at transcript level at six months after conver-
sion (Figure 3C), while no changes were observed in the control group. In two patients who were 
withdrawn from MMF and reconverted to CNI monotherapy, the proportion of Foxp3+ cells and 
Foxp3 mRNA expression decreased after re-introduction of CNI (Figure 3D). No association was 
observed between the percentage of Foxp3+ cells and the development of acute rejection. These 
findings suggests that CNI negatively affect the numbers of circulating Foxp3+ cells and that MMF 
does not have this negative effect.
To confirm the increase of Treg after conversion the proportions of CD4+CD25bright cells within 
total CD3+ T cells was determined. In Figure 4A and representative dot plots are shown for 
CD4+CD25bright cells. The mean proportion of CD4+CD25bright T cells increased significantly at six 
months after conversion from 1.2 ± 0.4 SEM at baseline to 2.6 ± 0.7 SEM at six months (Figure 
4B). At nine to twelve months after conversion, the proportions of CD4+CD25bright T cells remained 
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A B
C
significantly elevated. Also the percentage of CD4+CD25+CTLA-4+ within total CD3+ T cells was 
increased at six months after conversion from 2.0 ± 0.8 SEM at baseline to 4.3 ± 2.4 SEM (p<0.05, 
data not shown). None of these changes were seen in control group (Figure 4B). In sum, these 
data indicate that conversion from CNI to MMF increases the proportion of circulating T cells with 
a regulatory phenotype.
Figure 3C. Foxp3 mRNA analysis at baseline and at six 
months (n=11) confirmed the enrichment of Foxp3+ Treg 
after conversion (*p=0.002 compared to baseline), while 
Foxp3 levels in the controls on CNI did not significantly 
change (n=6). ( D ) In two patients who were re-conver-
ted from MMF to CNI a decrease in the percentage of 
CD4+Foxp3+ T cells and ( E ) Foxp3 mRNA levels was 
observed.
Figure 4. Increase percentage of CD4+CD25bright T cells 
after conversion to MMF monotherapy. ( A ) Represen-
tative dot plots of CD4+CD25bright cells within the CD3+ T-
cell population. The percentage of CD4+CD25bright cells in 
( B ) conversion (n=12) and ( C ) control patients (n=7). 
At one month after conversion to MMF the proportions of 
CD4+CD25bright cells significantly decreased compared to 
baseline, followed by an increase at six and nine to twelve 
months. At six months, 11 out of 12 patients showed a 
more than 25% increase in CD4+CD25bright cells. In the 
control patients on CNI, the percentage of CD4+CD25bright 
cells remained unchanged for all time points. Asterisks in-
dicates p<0.01 and bar indicates median.
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Phenotypical changes of Treg after conversion to MMF
One month after conversion to MMF, CD25 expression on CD4+ T cells was significantly decre-
ased (Figure 4B). At this time point the percentage of Foxp3+ cells remained unchanged (Figure 
3B). The CD25 down regulation was not due to epitope blocking because the antibody used (clone 
M-A251) for detection recognizes a different (independent) epitope than Daclizumab. Contrary, 
loss of CD25 expression is probably due to Daclizumab-associated receptor internalization or 
shedding. The increased CD25 expression on CD4+ T cells observed at six months after con-
version was predominantly confined to CD4+Foxp3+ cells (Figure 5A). A slight increase of CD25 
expression was observed on Foxp3- cells, but this did not reach statistical significance.
In order to determine the kinetics of CD25 blocking by Daclizumab, double immuno stainings were 
performed using a dependent and independent CD25 detection antibody. Results are shown in 
Figure 5B. Highest CD25 blocking was observed at one month after conversion (75%) and redu-
ced to baseline levels by six months. No significant difference in CD25 blocking was observed 
between CD4+Foxp3+ and CD4+Foxp3- cells (data not shown).
Figure 5. Changes in CD25 expression on Foxp3+ cells after conversion. ( A ) Relative to baseline, six months after conver-
sion CD25 expression significantly increased on Foxp3+ cells. On Foxp3- cells, CD25 expression also increased though to a 
lesser extent than Foxp3+ cells and not significantly different from baseline. At one month after conversion CD25 expression 
was significantly decreased on Foxp3+ and Foxp3- CD4+ T cells (* p<0.05). ( B ) Extent of CD25 blocking by Daclizumab 
of CD4+ T cells. Blocking was calculated based on differential staining of two CD25 detecting antibodies, one binding to the 
same epitope as Daclizumab and one binding a distinct epitope. Highest level of CD25 blocking (>75%) was observed at 
one month and returned to baseline at six months after conversion (n=9). In the control group (n=5) approximately 15 per-
cent CD25 blocking was observed which was unrelated to Daclizumab but could be related to bound IL-2.
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DISCUSSION
The success of solid-organ transplantation depends on the continuous administration of toxic and 
non-specific immunosuppressive drugs to prevent rejection. Currently, maintenance immunosup-
pressive therapy in most liver transplant recipients includes a CNI. This study shows that the per-
centage of Foxp3+ cells within the CD3+CD4+ T cells significantly increase after conversion from 
CNI to MMF and decreases again after reconversion from MMF to CNI (Figure 3). Conversion to 
MMF also resulted in phenotypical changes within the Treg population. After conversion an incre-
ase of CD25 expression level (i.e. mean fluorescence intensity) on Foxp3+ cells was observed 
suggesting that these cells may have become more susceptible to IL-2 signals.
IL-2 has been shown to be of critical importance for the function and survival of Treg (7, 15). Im-
munosuppression interfering with the IL-2 pathway may therefore affect the suppressive capacity 
and homeostasis of Treg. CNI interfere with the NFAT signaling pathway which is an important 
regulator of IL-2 production. Recently, a close relationship between NFAT and Foxp3 was shown 
to be critical for Treg function (16). By interfering with this interaction, CNI are thought to inhibit 
Treg (17). In experimental bone marrow transplantation CsA administration inhibited Treg function 
in vivo by reducing IL-2 production (5). Exogenous IL-2 was shown to overturn the suppressed 
Foxp3 expression and the suppressive function of Treg induced by cyclosporine A, underlining 
the importance of IL-2 for Treg. In this same study it was shown that rapamycin and MMF had no 
detrimental effect on the suppressive function of Treg, both in vitro and in vivo (5). There is now 
accumulating evidence that MMF like rapamycin spares Treg in their survival and function. It was 
shown in different experimental transplant models that MMF does not interfere with Treg function 
and positively effect tolerance induction (5, 9, 13). In the clinical setting, Segundo and coworkers 
recently demonstrated that the use of CNI, and not rapamycin, is associated with a reduced per-
centage of circulating Treg in renal transplant recipients (18). To our knowledge for the first time 
our study shows that conversion to MMF therapy can actually reverse the suppressive effect of 
CNI on the percentage of Treg in circulation.
In our study we showed that the percentage of CD4+Foxp3+ Treg increased after conversion from 
CNI to MMF. Interestingly, this increase was accompanied by a significant increase of CD25 ex-
pression on CD4+Foxp3+ Treg (Figure 5). However, one month after conversion, when over 75 
percent of CD25 is effectively blocked by Daclizumab, CD25 expression was significantly decre-
ased, both on CD4+Foxp3+ and CD4+Foxp3- cells. Kreijveld et al. (19) reported that during Daclizu-
mab treatment in kidney transplant recipients levels of Foxp3+ Treg decreased. In contrast, Kohm 
et al showed a functional inactivation, rather than depletion, of Treg by CD25 antibodies (20). 
These contradicting findings may be due to the intensive immunosuppressive therapy following 
kidney transplantation, which may act synergistically on Treg. In our study monotherapy with MMF 
in combination with one gift of Daclizumab did not result in decreased levels of CD4+Foxp3+ Treg 
one month after conversion, but in an increase at six months and beyond and was supported by 
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analysis of CD25bright (Figure 4) and CD25+CTLA-4+ T cells (not shown).
The possible negative effect of CNI on tolerance by affecting Treg is accompanied with non-im-
munological side effects, in particular nephrotoxicity, causing significant morbidity. This initially 
randomized study shows that conversion from a CNI based immunosuppressive regimen to MMF 
monotherapy improves renal function with a low risk of acute rejection, supporting previous con-
version studies in liver transplant recipients (11, 12). Two patients developed an episode of acute 
rejection, one at one month and the other at six months after conversion. The patient who develo-
ped acute rejection at six months after conversion had a MMF blood trough level of 1.8 mg/l at the 
time of rejection, while being approximately 7 mg/l in the months before. After initial improvement 
with steroids, biliary obstruction was diagnosed, which may have contributed to the portal cellular 
infiltrate seen in the liver biopsy. No difference in MMF trough levels were seen in the other patient, 
who developed acute rejection, and graft function normalized after treatment. 
In conclusion, we show that CNI withdrawal in liver transplant recipients increases the proportions 
of circulating CD4+Foxp+ Treg. Whether this has important implications on the balance between 
alloreactivity and tolerance remains to be determined. Clinically, conversion from CNI to MMF 
clearly results in an improvement of renal function and a decrease of blood pressure. 
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Part III 
Regulatory T cells in the liver

CHAPTER 6
Allo-suppressive donor CD4+CD25+ regulatory T cells detach from the 
liver graft and circulate in recipients after liver transplantation
Ahmet Demirkiran, Brenda M. Bosma, Alice Kok, Carla C. Baan, Herold J. Metselaar, 
Jan N.M. IJzermans, Hugo W. Tilanus, Jaap Kwekkeboom and Luc J.W. van der Laan
The Journal of Immunology, 2007, 178, 6066–6072
ABSTRACT
Organ transplantation (Tx) results in a transfer of donor leukocytes from the graft to the recipient, 
which can lead to chimerism and may promote tolerance. It remains unclear whether this tolerance 
involves donor-derived regulatory T cells (Treg). Here, we examined the presence and the allo-
suppressive activity of CD4+CD25+Foxp3+ Treg in perfusates of human liver grafts and monitored 
their presence in the circulation of recipients after liver Tx. Vascular perfusions of 22 liver grafts 
were performed with University of Wisconsin preservation and albumin solutions. Flowcytometric 
analysis revealed that perfusate T cells had high LFA-1 integrin expression and had a reversed 
CD4:CD8 ratio compared to control blood of healthy individuals. This indicates that perfusate cells 
are of liver origin and not derived from residual donor blood. Further characterization of perfusate 
mononuclear cells showed an increased proportion of CD4+CD25+CTLA-4+ T cells compared to 
healthy control blood. Increased percentages of Foxp3+ cells, which were negative for CD127, 
confirmed the enrichment of Treg in perfusates. In a mixed-leukocyte reaction, CD4+CD25+ T cells 
from perfusates suppressed proliferation and IFN-γ production of donor and recipient T cells. In 
vivo, within the first weeks after Tx up to 5% of CD4+CD25+CTLA4+ T cells in recipient blood were 
derived from the donor liver. In conclusion, substantial numbers of donor Treg detach from the 
liver graft during perfusion and continue to migrate into the recipient after Tx. These donor Treg 
suppress the direct pathway allo-responses and may in vivo contribute to chimerism-associated 
tolerance early after liver Tx.
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INTRODUCTION
Organ transplantation (Tx) results in a transfer of leukocytes present in the graft into the recipient. 
The migration of donor cells to host tissues results in chimerism and this has been proposed to 
be associated with donor-specific tolerance (1, 2). The relevance of these passenger leukocytes 
to Tx outcome has been demonstrated in several models showing significant roles in regulation 
of immune reactions after organ Tx. In a heart Tx model, selective antibody-mediated depletion 
of donor leukocytes leads to the prevention of tolerance induction and is associated with severe 
acute or chronic graft rejection (3). Similar results have been found in experimental liver Tx, in 
which depletion of passenger leukocytes leads to rejection of the graft in spontaneously tolerant 
recipients (4, 5). Reconstitution of donor leukocytes by intravenous injection recovers graft accep-
tance. Part of this recovery has been shown to be dependant on T cells, but not B cells or monocy-
tes/macrophages, as shown by selective deletion from the reconstituting donor leukocytes (6, 7). 
However, the exact mechanism of this so-called chimerism-associated tolerance remains unclear. 
It has been suggested that high levels of chimerism, like for instance following bone marrow Tx 
after myeloablation, are associated with tolerance through clonal deletion or anergy induction of 
host T cells. Low levels of chimerism, like for instance following solid organ Tx, are associated with 
tolerance through regulatory mechanisms, which may involve active suppression of allo-respon-
ses by regulatory T cells (Treg) (8, 9). Both in clinical and experimental liver Tx, chimerism and 
chimerism-associated tolerance is more frequently seen compared to other organ Tx (10, 11). 
Higher levels of chimerism in liver Tx are associated with reduced incidence of acute rejection and 
better initial graft acceptance (12).
Within the regulatory cell populations, CD4+CD25+ Treg play a critical role in various models of 
transplant tolerance (13-16). Regulation of allo-responses seems to depend in part on cytotoxic 
T lymphocyte antigen 4 (CTLA-4), which is constitutively expressed by Treg (17, 18). Bigenzahn 
et al showed that depletion of CD25+ cells shortly after non-myeloablative bone marrow Tx and 
co-stimulation blockade significantly reduced tolerance induction. This finding suggests that 
CD4+CD25+ Treg may be actively involved in chimerism-associated tolerance, in particular early 
after Tx (19). However, this remains controversial since other studies did not confirm a role for 
CD4+CD25+ Treg after bone marrow Tx (20, 21) .
To determine the specific role of donor leukocytes in the outcome of solid organ Tx it is important 
to phenotypically (22) and functionally characterize donor-derived leukocytes. In clinical liver Tx, 
the effluent solution passing through the graft livers during perfusion prior to Tx has been shown 
to be useful for this purpose. The leukocytes isolated from this perfusate solution represent deta-
ched liver-associated leukocytes, as shown by increased proportion of CD8+ cells that outnumber 
CD4+ cells and high natural killer cell numbers comparable with numbers in liver tissue (23, 24). 
Furthermore, the myeloid dendritic cell (DC) population present in the perfusates has an immature 
phenotype identical to DC isolated from liver tissue and producing higher amounts of IL-10 com-
pared to blood DC (24). 
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In the current study we determined the migration and suppressive capacity of donor CD4+CD25+ 
Treg from the liver graft into the perfusate and the recipient after Tx.  We show that the lymphocyte 
population that migrates from the human liver is enriched for CD4+CD25+Foxp3+ cells and that 
these cells suppress proliferation and IFN-γ production of recipient T cells in vitro. In addition, we 
demonstrate that donor-derived cells with a regulatory phenotype can be detected in substantial 
numbers in circulation of recipients after liver Tx. 
MATERIAL AND METHODS
Perfusate and peripheral blood collection
Liver perfusates were collected from 22 human liver grafts. During the back table procedure the 
grafts were perfused through the portal vein with 1 to 2 L of University of Wisconson solution to 
remove residual blood from the vasculature. Immediately before Tx, the donor liver was perfu-
sed with 200 up to 500 ml of human albumin-solution under hydrostatic pressure and the perfu-
sate was collected from the vena cava. Mononuclear cells from perfusate were isolated within 12 
hours by density gradient centrifugation using Ficoll Paque Plus (Amersham Biosciences, Up-
sala, Sweden). Peripheral blood mononuclear cells (PBMC) were obtained from fourteen healthy 
volunteers, which served as control. After isolation, cells were stored in 10% DMSO-containing 
medium at –180ºC. From six HLA-A2 negative liver recipients who received an HLA-A2 positive 
graft, blood samples were taken prior to and in the first weeks after Tx. From five liver transplant 
recipients peripheral blood was collected pre-Tx for functional assays. This study was approved 
by the Medical Ethical Committee of the Erasmus MC and informed consent was obtained from 
all participants.
Monoclonal antibodies
The following fluorochrome-conjugated monoclonal antibodies were used: CD25-APC, CD4-
PerCP-Cy5.5, IgG1-FITC and IgG1-APC from Becton Dickinson (San Jose, USA), CTLA-4-PE, 
CD3-FITC, CD3-PE and IgG2a-PE from Immunotech (Marseille, France), Foxp3-APC, CD127-
FITC and isotype IgG2a-APC from eBiosciences (San Diego, USA), CD11a from Biosource (Et-
ten-Leur, the Netherlands), secondary antibody (goat-anti-mouse) FITC, CD8-APC and CD4-APC 
from DAKO (Glostrup, Denmark). HLA-A2 staining was performed with an anti-HLA-A2 antibody 
derived from a hybridoma (clone BB7.2, ATCC HB-82) followed by an FITC-conjugated rabbit anti-
mouse IgG secondary antibody (DAKO).
Flow cytometric analysis
After thawing, liver perfusate mononuclear cells (LPMC) and PBMC were washed twice with 
phosphate-buffered saline (PBS) containing 0.3% bovine serum albumin (BSA) followed by stai-
ning with primary monoclonal antibodies CD3, CD4, CD8, CD25 and CD127 in PBS/0.3%BSA (30 
minutes at 4ºC). Following primary incubation cells were washed, and for staining of intracellular 
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CTLA-4 or Foxp3, the cells were fixed and permeabilized using the IntraPrep Reagents (Immu-
notech, Marseille, France) or fixation/permeabilization agents supplied by eBiosciences, respec-
tively. HLA-A2 positive cells were determined by incubation with anti-HLA-A2 antibody followed 
by staining with FITC conjugated anti-mouse IgG. Expression of leukocyte function-associated 
antigen-1 (LFA-1, CD11a) was determined in a similar manner by primary staining for CD11a fol-
lowed by secondary staining with FITC conjugated anti-mouse IgG. Flowcytomteric analysis was 
performed using FACS Calibur and CELLQuest Pro software (Becton Dickinson, San Jose, CA). 
CD4+CD25+ T cell isolation
CD4+ cells were purified from fresh LPMC and PBMC using the untouched CD4+ T-cell isolation kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). After washing with PBS/0.3% BSA, CD4+ T cells 
were incubated with anti-CD25 microbeads (Miltenyi Biotec) followed by a positive selection of 
CD4+CD25+ T cells according to manufacturer’s instructions. The CD4+CD25- fraction was used as 
responder cells. The purified Treg fraction contained more than 90% pure CD4+CD25+ T cells.
Mixed Leukocyte Reaction (MLR) and suppressor activity assays
Responder CD4+CD25- T cells of recipient and donor were labeled with 2 µM carboxyfluorescein 
diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR) and 1.0 x 105 cells per 
well were stimulated with irradiated (5 Gy) donor LPMC (5 x 104 cells) and recipient PBMC (5 
x 104 cells) in a 96-well round bottom plate. Cells were cultured in RPMI-1640 with L-glutamin 
(Cambrex Bioscience, Verviers, Belgium) supplemented with 10% pooled heat-inactivated human 
serum, 100 IU/ml penicillin and 100 μg/ml streptamycin in a total volume of 200µl. To determine 
the suppressive activity of CD4+CD25+ T cells isolated from LPMC and PBMC increasing num-
bers of CD4+CD25+ T cells (1.0 x 104 and 3.0 x 104) were added to the cultures. Cultures were 
performed in duplicates or triplicates. At day 4 of culture, 100µl  of culture medium was replaced 
and the concentration of IFN-γ was measured by ELISA (U-CyTech, Utrecht, The Netherlands). 
After 5 days, T-cell divisions were analyzed by flowcytometry by staining the cells with CD3 and 
CD4 antibodies. CFSE-flowcytometry data were analyzed by ModFitTM software version 3.0 (Verity 
Software House, Topsham, USA). The Proliferation Index (PI), which is the sum of the cells in all 
generations, divided by the computed number of original parent cells, indicates the extent of T-
cell expansion. If the PI is equal to one than no T-cell division took place during the course of the 
culture.
Statistical analysis
For the MLR and IFN-γ production, statistical analysis was performed by analysis of the loga-
rithmic transformation of the dependent variable with random intercept and random slope using 
PROC Mixed in SAS version 9.1. (SAS Institute Inc, Cary, NC). Significance of differences bet-
ween LPMC and PBMC flowcytometric results was determined with the Mann-Whitney test using 
SPSS Inc. software version 11.0 (Chicago, Ill, USA).
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RESULTS
LPMC are of liver origin
Perfusates were collected during the pre-Tx albumin perfusion of donor livers on the bench. With a 
mean ischemia time of 7±2 hours, the perfusates contained on average 91x106 mononuclear cells 
(range 10-500x106). Viability as determined by trypan blue exclusion showed that 98 ± 2% of the 
LPMC were vital. Liver lymphocytes are known to express higher levels of LFA-1 than lymphocy-
tes in peripheral blood (25, 26). Flowcytometric characterization of LPMC and PBMC showed that 
within the perfusates a significantly greater proportion of lymphocytes had high LFA-1 expression 
(Figure 1). The CD4:CD8 ratio in perfusates was 1.0:2.4 (n=22) and was significantly distinct from 
the ratio in blood (2.0:1.0, n=14, p<0.001). These findings indicate that leukocytes present in per-
fusates are predominantly liver derived and not derived from residual blood.
Figure 1A. High LFA-1 expression on CD4+ T cells from 
perfusates. Assessment of LFA-1 expression on CD4+ T 
cells  in LPMC and PBMC. Representative histogram sho-
wing higher LFA-1 (CD11a) expression on CD4+ T cells in 
LPMC compared to CD4+ T cells in PBMC. 
Figure 1B. The increased proportion of LFA-1highCD4+ T 
cells in perfusates suggests that these cells are of liver 
origin and not derived from residual donor blood. In per-
fusates (n=9) on average 81% of CD4+ T cells are LFA-
1high compared to 28% in PBMC of healthy controls (n=10). 
Shown are mean percentages + SEM. 
LPMC are enriched for CD4+CD25+CTLA-4+and CD4+CD25+Foxp3+ T cells 
In order to determine the presence of T cells with regulatory phenotype, CD25, CTLA-4 and 
Foxp3 expression within CD3+CD4+ T cells was assessed by flowcytometry. Figure 2A shows 
a representative dot plot of LPMC. As shown in Figure 2B, LPMC contained a median of 4.9% 
CD4+CD25+CTLA-4+ T cells (range 1.8-12.1%), significantly higher compared to 2.2% in PBMC of 
healthy controls (range 1.1-3.1%). 
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Figure 2A. LPMC CD4+ T cells contain a higher CD25+CTLA-4+ cell fraction compared to PBMC. FACS profile of 
CD3+CD4+CD25+CTLA-4+ cells. Within the CD3+CD4+ T cell population the proportion of cells expressing membrane CD25 
and intracellular CTLA-4 was determined. Shown are representative dot plots from a liver perfusate. Gates were based on 
isotype matched control stainings.
Gated on CD3+CD4+ cells
Figure 2B. Increased proportions of CD4+CD25+CTLA-4+ T cells in perfusates compared to peripheral blood. Median per-
centage of CD25+CTLA-4+ cells within CD3+CD4+ T cells is 4.9% (range 1.8-12.1)  in LPMC compared to 2.2% (range 
1.1-3.1) in PBMC.
A subset of perfusates was analyzed for Foxp3 expression. In Figure 3A a representative staining 
for Foxp3 expression in LPMC and PBMC is shown. Comparison of perfusate and peripheral 
blood revealed increased proportions of CD4+CD25+Foxp3+ T cells in perfusates (Figure 3B). RT-
PCR confirmed the presence of Foxp3+ T cells by analysis of Foxp3 transcript levels in perfusates 
(data not shown). Analysis of CD127, the IL-7 receptor, showed that the majority of perfusate 
Foxp3+ cells were negative for CD127 identical to Foxp3+ cells in blood (Figure 3C and 3D). In 
sum, these data indicate that a considerable proportion of helper T cells that detach from the liver 
during perfusion have a regulatory phenotype.
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Perfusate CD4+CD25+ T cells inhibit proliferation and IFN-γ production of donor and 
recipient responder T cells
To test the suppressive activity of CD4+CD25+ T cells in LPMC, we performed a MLR using CFSE 
fluorescent-labeled responder T cells. First, we tested the suppressive activity of CD4+CD25+ cells 
in the autologous setting. Donor CD4+CD25- responder cells (1 x 105) from LPMC were mixed with 
two different concentrations of donor CD4+CD25+ T cells leading to a dose-dependent inhibition of 
proliferation as shown in Figure 4. Also the autologous suppressive activity of recipient CD4+CD25+ 
T cells from PMBC was demonstrated. Notably, the proliferation of perfusate CD4+CD25- T cells 
was less extensive compared to recipient blood responder T cells. However, the suppressive acti-
vity of perfusate CD4+CD25+ T cells was intact.
Next we tested the suppressive activity of perfusate CD4+CD25+ T cells in an allogeneic setting. As 
antigen-presenting cells, both irradiated PBMC (5 x 104) and LPMC (5 x 104) were used together in 
order to simultaneously activate recipient (responder) and donor (suppressor) T cells. Both perfu-
sate and recipient CD4+CD25+ cells showed no proliferation in response to allogeneic stimulation, 
Figure 3. Increased percentage of CD4+CD25+Foxp3+ cells in LPMC compared to PBMC.  Assessment of CD4+CD25+Foxp3+ 
T cells in perfusate and PBMC. Within the CD3+CD4+ T cell population the proportion of cells expressing CD25 and Foxp3 
was determined. ( A ) Representative dot plot of perfusate  is shown. ( B ) Increased CD25+Foxp3+ cells in total CD4+ T cells 
in perfusates compared to PBMC. Almost all CD4+Foxp3+ were positive for CD25.  
Figure 3C. Representative dot plot showing CD127 expression on perfusate CD4+ cells. ( D ) The majority of perfusate 
CD4+Foxp3+ cells (n=4) are CD127 negative comparable to the expression in blood CD4+Foxp3+ cells (n=6).
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Figure 4A. Perfusate CD4+CD25+ T cells inhibit proliferation of both recipient and donor responder T cells. Representative 
MLR showing CFSE staining of control recipient CD4+CD25- T cells (1 x 105) in the absence (left) and presence of perfusate 
CD4+CD25+ T cells (3 x 104) (right) upon stimulation with irradiated donor and recipient mononuclear cells. The number of 
cells in the daughter generations are significantly lowered in the presence of perfusate CD4+CD25+ T cells.
Figure 4B. Effect of perfusate and recipient CD4+CD25+ T cells on proliferation of recipient and donor CD4+CD25- T cells. 
Proliferation of recipient (1 x 105) and perfusate responder cells (1 x 105)  was significantly (* p=0.034 and ** p=0.032, 
respectively) inhibited by perfusate CD4+CD25+ T cells (black and white bars, respectively). Responder cells were stimu-
lated with irradiated donor (5 x 104) and recipient mononuclear cells (5 x 104). As a positive control the suppressive activity 
of recipient CD4+CD25+ T cells was also determined (gray bars, *** p=0.003). Significance was tested by analysis of the 
logarithmic transformation of the dependent variable with random intercept and random slope. Shown is the mean ± SEM 
of 5 experiments. 
indicating a state of anergy (data not shown). When CD4+CD25+ T cells from LPMC were added to 
recipient CD4+CD25- responder cells, we observed significant suppression of proliferation compa-
rable to the inhibition observed in the autologous setting (Figure 4). Consistently, when looking at 
the IFN-γ production in these MLR similar results were found showing dose-dependent inhibition 
by donor CD4+CD25+ T cells of donor and recipient IFN-γ production (Figure 5). The suppression 
of both proliferation and IFN-γ production suggests that CD4+CD25+ T cells from the liver are able 
to suppress the direct-pathway allo-response in vitro.
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Figure 5. Inhibition of IFN-γ production by perfusate CD4+CD25+ T cells. 
CD4+CD25+ T cells inhibit IFN-γ production by effector CD4+CD25- T cells. Shown are the mean relative inhibition of IFN-γ 
production (±SEM) for three experiments, as determined by ELISA. Perfusate CD4+CD25+ T cells inhibit IFN-γ produc-
tion of recipient responder CD4+CD25- T cells (black bars, p=0.03) and of perfusate responder CD4+CD25- T cells (white 
bars, p=0.004). Recipient CD4+CD25+ T cells inhibit IFN-γ production of recipient responder CD4+CD25- T cells (grey bars, 
p=0.07).
CD4+CD25+CTLA-4+ T cells detach from the liver graft after Tx and circulate in recipients
In order to determine whether donor T cells with a regulatory phenotype can be detected in re-
cipients after liver Tx, we performed flowcytometric analysis of PBMC from HLA-A2 negative re-
cipients who received an HLA-A2 positive liver graft. Determination of HLA class 1-A2 allele has 
previously been shown to be useful to distinguish between donor and recipients cells (27, 28). A 
representative staining is shown in Figure 6A.  In the first week after Tx 3.1± 1.0% SEM of the total 
CD4+ T cells and 2.5 ± 1.0% SEM of the CD4+CD25+CTLA-4+ cells were found to be of donor origin 
(Figure 6B). These percentages of donor cells increased initially and gradually declined at one and 
six months after Tx. Similar results were found when analyzing the percentage of HLA-A2+ cells 
within the CD4+CD25+Foxp3+ fraction (n=4, data not shown). The proportion of CD25+CTLA-4+ 
cells within CD4+ cells was significantly higher in donor-derived than in recipient cells (Figure 6C). 
Also at 6 months there was a difference although the overall percentage of CD4+CD25+CTLA-4+ 
cells was declined at this time point. These data indicate that donor T cells with a regulatory phe-
notype migrate from the liver graft into the circulation of recipients.
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Figure 6A. Donor CD4+CD25+CTLA-4+ T cells circulate in recipients after liver Tx.  Representative dot plots showing donor HLA-
A2+ cells in recipient blood one week after Tx. Pre-Tx recipient PBMC and donor spleen cells serve as negative and positive 
control, respectively. The expression of CD25 and CTLA-4 of HLA-A2 positive and negative CD4+ cells is shown.
Figure 6B. Proportions of HLA-A2+ cells within the CD4+ cells and within CD4+CD25+CTLA-4+ cells are highest at one 
week (n=6) and gradually decrease at one (n=4) and six months after Tx (n=4). ( C ) One week and six months after Tx the 
proportion of donor CD4+CD25+CTLA-4+ cells within the donor CD4+ cells was increased compared to the proportions of 
CD4+CD25+CTLA-4+ cells within recipient CD4+ cells (* p<0.05). Both recipient and donor CD4+CD25+CTLA-4+ cells decrease 
at one and six months after Tx, although not reaching statistical significance due to small sample size.
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DISCUSSION
The unique immunological properties of the liver have partly been attributed to the resident leu-
kocyte population. Following liver Tx, donor leukocytes present in the graft are transferred and 
persist in recipients, a condition referred to as chimerism. In this study we aimed to investigate the 
presence of Treg in liver graft perfusion solution and in recipient blood after Tx. Within perfusate 
CD3+CD4+ T cells an increased proportion of CD25+CTLA-4+ and CD25+Foxp3+ T cells were found 
as compared to peripheral blood of healthy controls (Figures 2 and 3). Foxp3 mRNA expression in 
LPMC confirmed the presence of Treg (data not shown). Leukocytes in recipient circulation were 
shown to contain substantial numbers of donor CD4+CD25+CTLA-4+ T cells indicative of a regu-
latory signature (Figure 6). The functionality of donor Treg was studied in MLR, showing inhibition 
of proliferation of self- and recipient-responder CD4+CD25- T cells upon stimulation with donor 
and recipient mononuclear cells (Figure 4). Furthermore, the cytokine production was significantly 
inhibited, confirming the suppressive activity of CD4+CD25+ T cells within the LPMC (Figure 5).
The number of mononuclear cells obtained from perfusates showed a wide range, but did not cor-
relate with ischemia time or perfusate volume (not shown). Immunophenotypic characterization of 
LPMC shows clearly differences compared to PBMC, yet comparable with leukocyte subsets ob-
tained from liver tissue (23, 24). Our results show significantly lower proportions of CD4+ T cells and 
higher proportions of CD8+ within total LPMC T cell population compared to peripheral blood. Previ-
ously, it was shown that liver infiltrating T cells have high expression levels of the β2-integrin, LFA-1 
(22, 25). Therefore we determined the expression of LFA-1 α-chain (CD11a), which is expressed 
exclusively on leukocytes, and is involved in migration into tissues. The CD4+ T cells in perfusates 
have a strong LFA-1 expression, which is significantly higher compared to CD4+ T cells in PBMC 
(Figure 1). The strong adhesion molecule expression and the reversed CD4:CD8 ratio indicates that 
these cells originate from the liver tissue and have a pre-activated phenotype (22, 29). 
Within the CD4+ T cell population obtained from perfusates, a considerable proportion of T cells 
with a regulatory phenotype was observed. Treg characterized by CD4, CD25, CTLA-4 and Foxp3 
expression were significantly increased compared to peripheral blood levels in healthy controls 
(Figures 2 and 3). Recently, the absence of the IL-7 receptor expression, CD127, has been sug-
gested as a discriminating factor of Foxp3+ Treg (30, 31). Our analysis showed that the majority of 
liver-derived Foxp3+ cells were CD127 negative, which was comparable to control blood (Figure 
3D). To our knowledge this is the first study to show the presence of CD4+CD25+Foxp3+ T cells 
as passenger leukocytes in liver grafts. Following liver Tx, a substantial proportion of circulating 
leukocytes are of donor origin (28) and even higher in case of graft-versus-host disease (32). In 
the first week after Tx, we have shown that up to 5% of total CD4+CD25+CTLA-4+ T cell population 
were of donor origin (Figure 6B), equivalent to approximately 5 to 15 x 106 cells. The proportion 
of CD4+ cells which expressed CD25 and CTLA-4 was higher in donor cells than in recipient cells 
at one and six months after Tx (Figure 6C). Both donor and recipient CD4+CD25+CTLA-4+ cells 
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decreased in time after Tx. This general drop of CD4+CD25+CTLA-4+ Treg was consistent with our 
previous studies (33, 34). 
Katz et al have shown that hepatic CD4+ T cells are functionally suppressed by environmental 
factors (35), which may explain the low proliferative capacity of CD4+CD25- responder cells from 
LPMC in our study. As we have shown that a relatively increased proportion of CD4+ T cells pre-
sent in the liver have a regulatory phenotype, one might postulate that hepatic Treg are involved in 
mediating suppression of responses to antigens presented in the liver. In the context of Tx, these 
hepatic Treg may suppress not only allo-antigen-specific recipient T cells  but also DC and thereby 
inhibit the immune response against the graft. In our previous study we have shown that hepatic 
DC have an immature phenotype and produce high amounts of IL-10 (24). Experimental evidence 
suggests that immature DC can mediate tolerance, presumably by the induction of Treg (36, 37). 
Furthermore, in vitro, immature DC can induce allo-antigen-reactive Treg (38). Liver-derived DC 
are able to downregulate immune responses and stimulate T cells to produce IL-10 and IL-4 (39-
41). On the other hand, Treg limit the ability of DC to stimulate T cells and enhance the ability of 
DC to induce anergy concomitant with an increase in CTLA-4 expression (42-44). This way a 
bidirectional interaction may occur between liver T cells and DC, which may explain the unique 
hepatic microenvironment that is known to promote tolerance.
In this study we have shown that donor CD4+CD25+ T cells originating from the liver graft are able 
to suppress responder T cells from both recipient and donor. This observation suggests that Treg 
can suppress across a MHC barrier. This is consistent with previous findings showing that Treg 
suppress antigen non-specific once activated through their TCR (45). Furthermore, recently it was 
shown that allogeneic Treg can inhibit MHC-disparate responder T cells (46). These data indicate 
that chimerism of donor Treg may contribute to suppression of the direct pathway alloresponse 
that is the dominant antigen presentation pathway driving rejection early after Tx. The immuno-
logical relevance of donor leukocytes for allograft acceptance is particularly evident during the 
early phase after Tx (3). As we have shown that CD4+CD25+ T cells are functional in suppressing 
responder cells, one might postulate that these cells participate in the silencing of donor reactive 
T cells. These findings fit with the possibility that chimerism plays a key role in acquired Tx tole-
rance. 
Donor leukocyte migration and chimerism are associated with transplant tolerance both in the 
clinical and experimental setting (1, 2, 47). Depletion of donor leukocytes or failure to develop 
chimerism were shown to result in prompt rejection, but chimerism by itself is not sufficient to 
prevent rejection. In clinical Tx, the beneficial effect of donor leukocytes was clearly shown by 
pre-transplant blood transfusions leading to enhanced graft survival (48, 49). It is evident that 
donor leukocytes are important during the first weeks post-Tx in which maximal donor migration 
and interaction with host leukocytes occur. The exact mechanism in achieving tolerance through 
chimerism, however, has not been elucidated. Several mechanisms have been proposed in this 
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process including clonal exhaustion or deletion, T-cell anergy and active suppression (8, 10). Alt-
hough the cell interactions are indisputably complex, tolerance to skin transplants following bone 
marrow Tx was CD4+CD25+ Treg dependent mostly so early after Tx (19). Conversely, in bone 
marrow Tx an important role for CD4+ Treg has recently been identified in the induction of chime-
rism-associated tolerance, which was CD25 independent but CTLA-4 dependent (20). Whether 
graft-derived donor Treg influence the balance between the immunogenicity and tolerogenicity of 
organ allografts remains to be determined.
In conclusion, substantial numbers of donor Treg detach from the liver graft during perfusion and 
continue to migrate into the recipient after Tx. These donor Treg are functional in suppressing 
the direct pathway allo-responses in vitro and may therefore contribute to chimerism-associated 
tolerance early after liver Tx.
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CHAPTER 7
Low IL-10 gene expression levels in liver and blood 
during acute rejection after liver transplantation
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ABSTRACT
The presence of CD4+Foxp3+ regulatory T cells (Treg) in the transplanted graft, causing local 
suppression, has been linked to the outcome of transplantation (Tx) in several animal models. 
The aim of this study was to investigate cytokine expression levels and the early presence of 
Foxp3+ Treg in the graft after clinical liver Tx using a minimally invasive biopsy technique.
Blood and liver fine-needle-aspiration biopsy (FNAB) samples were taken at 7 to 21 days and 
6 to 12 months post-Tx. Quantitative RT-PCR analysis was performed for Foxp3, IFN-γ, IL10, 
TGF-β, TCR-Cα and 18S mRNA. Flowcytometry was used to determine CD4+Foxp3+ cells. 
Early after Tx IFN-γ expression was increased in the liver compared to blood, while at 6 
months IL-10 and TGF-β expression was higher in the liver. Recipients developing acute 
rejection (n=4) showed significantly lower IL-10 expression within the liver (p=0.014) and in 
blood (p=0.002) during acute rejection, while later no differences were seen. Even though no 
difference was seen with relative Foxp3 mRNA levels, higher numbers of Foxp3+ cells within 
the CD4+ T-cell population was observed in the liver compared to blood with flowcytometric 
analysis of non-rejectors (n=7, p<0.05). This difference was less apparent during acute rejec-
tion.  
This study shows that aspiration biopsy is a powerful approach to study intragraft gene ex-
pression patterns of cytokines and Treg after Tx, which provides relevant information regar-
ding allo-reactive and allo-regulatory responses. 
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INTRODUCTION
In the past decade CD4+ regulatory T cells (Treg) have emerged as critical players in media-
ting tolerance to self-and non-self antigens. Characterized by Foxp3, a key regulator for Treg 
function, these cells are able to prevent auto-immune diseases and to induce and maintain 
transplant tolerance, eliminating the need for high-dose immune suppressive therapy (1-5). 
In the past decade many studies have been realised to reveal the functional and homeos-
tatic characteristics of these cells. Data from animal studies suggest that at least part of the 
suppressive activity of Treg occurs in the transplanted organ itself (6, 7), including the liver 
graft (8). The presence of Foxp3+ Treg in the transplanted organ was much higher when the 
graft was tolerated compared to rejected grafts. This implies that the measurement of Treg 
presence in the transplanted organ may serve as a marker to determine graft acceptance. 
Previously, we and others showed that indeed Treg can be detected in the transplanted graft 
(9, 10). Within the liver graft Foxp3 expression increased in time, while in heart transplants hi-
ghest Foxp3 expression was observed during acute rejection. Immune activating and immune 
suppressive cytokines play a central role in the process of rejection and tolerance. A study by 
Bishop et al. showed that IL-2 and IFN-γ expression are increased during acute rejection and 
that chronic rejection was associated with low IL-10 expression in the liver graft (11). 
Differences between the immunological status in the graft as compared to peripheral blood 
emphasizes the need to further characterize the intragraft immune events. The major limita-
tion to investigate intragraft parameters in the clinical setting is the risk of complications as-
sociated with obtaining tissue biopsies. To obtain tissue from the liver for diagnostic purposes 
the core-needle biopsy is generally used, which is performed under local anesthetics and can 
cause serious complications due to damage of intercostal space, intrahepatic blood vessels 
or biliary tracts. As a less traumatic alternative, the fine-needle aspiration biopsy (FNAB) has 
been successfully introduced for the detection of allograft rejection and was shown to be as 
effective as the core-needle biopsy (12-14). The diameter of this needle is significantly smaller 
and therefore does not require anesthetics and has minimal risk of serious complications. In 
FNAB from the liver, inflammatory leukocytes (including T lymphoblasts and B plasmablasts), 
plasma cells, lymphocytes and monocytes are present (15). This technique has been shown 
to be useful for cytological, immunocytochemical (16) and flowcytometric analysis (17, 18), 
and gene expression analysis (9). 
The aim of the current study is to use FNAB of the liver to determine the presence of Foxp3+ 
Treg and analyze intrahepatic gene expression levels of Foxp3 and cytokines associated with 
immune activation and regulation. Here, we present data that within the first month after liver 
Tx IFN-γ expression is increased in liver compared to blood. Furthermore, expression of IL-10 
was high in non-rejection and lower when rejection was developed. Cellular analysis showed 
that early after Tx the helper T-cell population in the liver contains higher levels of Foxp3+ Treg 
compared to blood. 
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PATIENTS AND METHODS
Patients
Patients who had undergone orthotopic LTx at the Erasmus MC-University Medical Center 
were consecutively enrolled. Standard immunosuppressive therapy consisted of anti-CD25 
mAb (Basiliximab) induction therapy (i.v. 20 mg at day 0 and day 4 post-Tx), calcineurin inhi-
bitions (Cyclosporin A or Tacrolimus) and steroids. Steroid treatment with Prednisone started 
with 20 mg daily from day 0 and was gradually weaned within 3 months. Acute rejections were 
clinically and histologically diagnosed in liver biopsies according to the Banff classification 
criteria. The Medical Ethical Committee of the Erasmus MC approved this study and an ap-
propriate informed consent was obtained from all patients.
Liver aspiration biopsy and peripheral blood mononuclear cells (PBMC) 
Fine-needle aspiration biopsies (FNAB) from the liver were performed as previously descri-
bed (9). Briefly, the liver aspiration was carried out by ultrasound guidance, followed by a 
macroscopically and microscopically evaluation. Only representative FNAB specimens, i.e. 
containing at least seven hepatocytes per 100 leukocytes, were analyzed (25). Heparinized 
peripheral blood was collected at the time of the FNAB. PBMC were obtained by density gra-
dient centrifugation over Ficoll-Paque plus (Amersham Biosciences, Buckinghamshire, UK). 
The FNAB specimens were partially used for flowcytometric analysis and partially for gene 
expression analysis. 
RNA extraction and real time reverse transcription polymerase chain reaction (RT-PCR)
Isolation of RNA was performed as previously described (9). In summary, erythrocytes were 
lysed from PBMC (1 x 106 cells) and FNAB with a hypotonic buffer, which also caused lysation 
of the hepatocytes. The remaining leukocyte fraction was suspended in 0.5 ml TRIzol reagent 
(Life Technologies, GmbH, Karlsruhe, Germany). Total RNA was extracted and precipitated 
with ice-cold 80% ethanol (350 µl). RNA was isolated from the precipitated solution using a 
RNA-isolation kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructi-
ons. Total RNA was denaturated for 10 min at 80°C and then chilled to 4°C.
The isolated RNA was incubated with hexanucleotides (Promega Corporation, Madison, WI) 
and transcribed with reverse transcriptase (Life Technologies, Gaithersburg, MD) at 42°C for 
90 min. The reaction mixture (20 µl) consisted of 2 µl (1000 U) of reverse transcriptase, 8 µl 
of 5 x reverse transcriptase buffer (250 mM Tris-HCl, pH 8.3, 15 mM MgCl2, 375 mM KCl), 2 
µl of dNTP (10 mM), 0.4 µl (800 U) of RNAsin (Promega), 0.4 µl of Random Primers, 4 µl (0.1 
M) of dithiothreitol and 3.2 µl of DEPC-H2O.
Quantification of Foxp3, IFN-γ, IL-10 and TGF-β mRNA was done with RT-PCR. As reference 
genes the constant region of the T cell receptor α chain (TCR-Cα) and the ribosomal 18S 
RNA were used. For relative quantification of the cytokines IL-10 and TGF-β, 18S RNA was 
used, as these genes are not exclusively expressed in T cells. Amplifications were performed 
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using the ABI 7700 sequence detector system (Applied Biosystems). Negative controls (no 
template), and positive reference samples were included repetitively for each determination, 
thereby verifying run-to-run variations. Samples negative for the TCR-α or 18S gene were 
excluded from further analysis. The relative gene expression was calculated based on the 
comparative ΔΔCt method with the TCR-α or the 18S expression in peripheral blood of blood-
bank donors (18). The following formula was used: ΔΔCT (Ct Target – Ct TCR-α) sample - (Ct 
Target – Ct TCR-α) control. The fold change was calculated using 2 
–ΔΔCt. Primers and probes for 
Foxp3, IFN-γ, IL-10, TGF-β and 18S were obtained from Assays-on-Demand Gene Expres-
sion Product and pre-developed Taqman PDAR assays (Applied Biosystems). The choice of 
primer and probe for the measurement of TCR-α transcripts was defined by using the primer 
express software (Applied Biosystems, Foster City, CA). The used sequences were for TCR-α 
were as previously described (10). 
Flow Cytometric Analysis
PBMC were obtained by density gradient centrifugation over Ficoll-Paque plus (Amersham Bi-
osciences, Buckinghamshire, UK). After washing twice with phosphate-buffered saline (PBS) 
containing 0.3% bovine serum albumin (BSA) PBMC and FNAB specimens were stained with 
monoclonal antibodies in PBS/0.3%BSA (30 minutes at 4ºC). The following fluorochrome-
conjugated monoclonal antibodies were used: CD25-PE, CD4-PerCP-Cy5.5 from Becton 
Dickinson (San Jose, USA), CD8-FITC and IgG2a-PE from Immunotech (Marseille, France), 
Foxp3-APC and isotype IgG2a-APC from eBiosciences (San Diego, USA). Intracellular Foxp3 
was stained after fixation and permeabilization using proper agents supplied by eBiosciences. 
Flowcytometric analysis was performed using FACS Calibur and CELLQuest Pro software 
(Becton Dickinson, San Jose, CA). 
Statistics
Statistical analysis was performed using software package SPSS version 11.5 (SPSS, Chi-
cago, IL). Significance was tested using the Wilcoxon paired test or the Mann-Whitney U 
unpaired test. P-values less than 0.05 were considered significant.  
RESULTS
Cytokine expression kinetics in liver versus blood
From eleven liver transplant recipients FNAB were taken in the first month after liver Tx. None 
of the recipients developed complications due to the FNAB procedure. The quality of FNAB 
specimens was confirmed by microscopic analysis of the hepatocyte/leukocyte ratio and bi-
opsies with blood contamination were excluded from further analysis. In four patients FNAB 
were taken during acute rejection confirmed with core needle biopsy. IFN-γ, IL-10 and TGF-β 
expression at early time points were compared to expression levels at six to twelve months 
after Tx in another cohort of patients (n= 20).  
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The expression of IFN-γ, IL-10 and TGF-β cytokines associated with immune activation and 
regulation, were determined by real-time RT-PCR. Relative expression was calculated based 
on the TCR-Cα mRNA levels, thereby allowing a comparison of T cell-related gene expres-
sion within liver and blood compartments. The universally expressed ribosomal 18S RNA was 
used as a reference gene for relative quantification of the cytokines IL-10 and TGF-β, which 
are not predominantly expressed in T cells. As shown in Figure 1, compared to blood the liver 
had a significantly higher expression of IFN-γ early after Tx (p=0.002), while at 6 months and 
later the expression was not different (Figure 1A). On the contrary, the expression of IL-10 and 
TGF-β was comparable early after Tx, but was significantly higher expressed in the liver at six 
to twelve months after Tx. These data suggest that early after Tx immune activating cytokines 
are predominantly expressed within the liver followed by dominating suppressive cytokine 
expression, suggesting a regulatory environment. 
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A
B
Figure 1. Differential IL-10, TGF-β and IFN-γ gene expression in liver and blood early (first 21 days) and late (6-12 
months) after Tx. Gene expression was analyzed by quantitative RT-PCR for fourteen FNAB and blood samples at one 
month  (left graphs) and twenty three at six to twelve months (right graphs) after Tx. IFN-γ  expression was significantly 
higher expressed in the liver (A). At six to twelve months after Tx IL-10 and TGF-β expression was significantly higher in 
liver, but not IFN-γ (B and C). Comparisons were done using the Wilcoxon signed ranked test. Bar indicates median. 
Cytokine expression in liver and blood during acute rejection
The gene expression in relation to the occurrence of acute rejection within one month after 
Tx was determined in liver and blood. Four of eleven recipients experienced an episode of 
biopsy-proven (RAI ≥5) acute rejection. As shown in Figure 2A, relative IL-10 levels in the 
liver of rejectors were significantly lower compared to non-rejectors (median 414 versus 1792, 
p=0.014). Also IL-10 gene expression in peripheral blood was significantly different between 
rejectors and non-rejectors (Fig 2B). TGF-β levels in liver and blood showed no difference 
between these groups (data not shown). Relative expression of IFN-γ was not determined. 
Figure 2. Acute rejection is associated with low IL-10 expression in liver and blood. In the first month after Tx, liver 
transplant recipients who were free of rejection had significantly higher IL-10 expression compared to recipients 
who developed acute rejection. Comparisons were done using the Mann Whitney U test. Bar indicates median.
C
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Foxp3+ Treg levels in liver and blood early after Tx
To determine the presence of T cells with a regulatory phenotype, CD25 and Foxp3 expres-
sion within CD4+ T cells was assessed by flowcytometry in a subset of patients. Figure 3A 
shows representative dot plots of Foxp3+CD4+ T cells in liver and blood samples. As shown 
in Figure 3B, in recipients who did not develop rejection CD4+ T cells contained significantly 
higher numbers of Foxp3+ cells in liver compared to blood (median 8.4 vs 5.8%, p=0.031). 
On the contrary, intrahepatic Foxp3 mRNA expression levels were not different compared 
to blood (n=14). Comparison of CD25 expression within the CD4+ T cells revealed a higher 
proportion in the liver compared to blood (median 37.3 vs 28.7%, Figure 3C). The number 
of patients developing rejection was not sufficient for statistical analysis. This suggests an 
increased T cell activation state and elevated Treg levels in the liver graft early after Tx as 
compared to the blood compartment. 
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BLOODLIVER
Figure 3. Increased proportion of Foxp3+CD4+ Treg in the liver compared to blood. (A) Representative dot plots showing 
flowcytometric analysis of CD4+Foxp3+ Treg in liver and blood. Within the intrahepatic CD4+ T-cell population of non-
rejectors, an increased proportion of T cells expressing Foxp3 was observed compared to blood (B). Analysis of CD25+ 
cells within total CD4+ T cells showed higher percentages within the liver early after Tx. No statistical analysis could be 
performed for recipients who developed acute rejection due to small numbers.
DISCUSSION
The ability to accurately quantify anti-donor immunity is an important issue in clinical Tx. Bet-
ter understanding of immune reactivity and immune regulation may facilitate safe adjustments 
in immunosuppressive treatment or even complete withdrawal in case of apparent transplant 
tolerance. Major research efforts are done to develop methods for immune monitoring and 
detection of transplant tolerance. Our analysis of gene expression with RT-PCR revealed dif-
ferential expression of the immune activating cytokine IFN-γ in liver compared to blood (Figure 
1), suggesting an increased activation status in the liver. No differences were observed for the 
other investigated genes in the first month. The expression of IFN-γ in relation to acute rejec-
tion requires further analysis. Interestingly, levels of IL-10 and TGF-β mRNA remained highly 
expressed in the liver at 6 to 12 months after Tx and dropped in blood, which indicates an 
immune controlled environment within the liver. During acute rejection the relative expression 
of IL-10 was significantly lower in liver and blood, while Foxp3 expression did not differ. Also, 
in the non-rejectors no difference was observed in Foxp3 expression between liver and blood. 
In contrast, analysis of Fopx3+ cells within the CD4+ T-cell population in the liver, revealed an 
increased level of Foxp3+ cells compared to levels in blood. The discrepancy between the 
gene expression data and flowcytometric protein analysis may be due to the method of analy-
sis. With flowcytometry the Foxp3+ cells are determined within the CD4+ T-cell population, as 
for the PCR analysis the expression of Foxp3 was determined relative to the TCR-Cα mRNA, 
which is also expressed in the extensive population of CD8+ cells in the liver, which practically 
do not express Foxp3 in the liver (Claassen, unpublished data).    
IL-10 has been implicated in controlling cellular immune responses (20, 21), indicating that 
IL-10 may be crucial in the unique immune tolerogenic environment of the liver. In the setting 
of liver Tx, the addition of neutralizing IL-10 antibody showed remarkable increase of the anti-
donor immune response as measured in a trans-vivo delayed type hypersensitivity response 
(22). Our results support these data showing lower expression of IL-10 during acute rejection, 
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suggesting an important role for IL-10 in the development or course of rejection. A recent 
study by Gras and collegues showed that  liver transplant recipients who accepted their graft 
showed markedly increased IL-10 levels in blood early after Tx, whereas recipients with graft 
rejection did not (23). Furthermore, T cells from tolerant liver transplant recipients showed 
increased IL-10 production, associated with increased CD4+CD25high Treg (24). In kidney Tx, 
the ratio between IFN-γ and IL-10 gene expression has been shown to be relevant for im-
mune monitoring (25). The importance of IL-10 in transplant outcome was shown by Yang 
and colleagues suggesting a close relationship of IL-10 and induction of long-term liver allo-
graft survival (26). IL-10 recombinant protein was shown to augment the expression of Foxp3 
and downregulate the expression of IL-2 and IFN-γ. Importantly, this was accompanied by 
the generation of CD4+CD25+Foxp3+ and CD8+CD25+Foxp3+ cells, which was blocked by the 
administration of IL-10 antibody. In addition, Foxp3+ Treg are shown to give rise to peripheral 
IL-10+ Treg, underlining the close relationship between Foxp+ Treg and IL-10 (27). In the liver, 
an enrichment of Foxp3+IL-10- Treg was observed. Our data showed a lower expression level 
of IL-10 during acute rejection. Whether this results in lower Foxp3+ Treg numbers needs to 
be determined. Several studies have linked IL-10 expression to hyporesponsiveness against 
the graft. Bishop et al. noticed that in chronic rejected liver transplants IL-10 expression was 
significantly lower compared to acute rejection and normal liver (11). In heart Tx high IL-10 ex-
pression was associated with donor-specific cytotoxic hyporesponsiveness. Altogether these 
findings suggest an important role for the immunomodulatory cytokine IL-10 in the course of 
rejection/tolerance. 
Acute allograft rejection episodes are characterized by an influx of donor-reactive T cells in the 
graft. Accordingly, this is accompanied by a prominent increase in mRNA of pro-inflammatory 
cytokines, such as IL-2 and IFN-γ (11, 28, 29). A recent study by Baan et al showed that du-
ring a rejection episode of cardiac allografts relative expression of Foxp3 increased (10). This 
finding could indicate an influx or local induction of Foxp3+ T cells in the transplanted organ at 
the time of rejection. Our results for liver Tx showed a significant higher proportion of Foxp3+ 
cells within the helper T cells in the liver. The level of Foxp3+ Treg in relation to acute rejection 
requires further analysis. Interestingly no differences were seen in Foxp3 mRNA expression 
early after liver Tx, while relative expression was increased at 6 months after Tx (9).  In kidney 
Tx levels of Foxp3 mRNA present in urine have been suggested as a biomarker of acute-re-
jection outcome, with lower levels associated with irreversible acute rejection and even graft 
failure (31). Altogether, better understanding of the relationship between Foxp3, immune acti-
vating/regulating cytokines and acute rejection may help to distinguish transplant outcome. 
Increasing evidence shows that measurement of intragraft immunological parameters is as 
important or even more important compared to parameters in blood. Here, we show that the 
FNAB may be a favourable alternative for intragraft immune monitoring by intragraft analysis 
of cell composition and gene expression. In liver transplant recipients the proportion of CD4+ T 
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cells with a regulatory phenotype was increased compared to blood within the first month after 
Tx. This finding could indicate that Foxp3+ cells of the recipient traffic into the graft or may be 
locally induced after liver Tx. However, whether this Treg accumulation represents the begin-
ning phase of tolerance to the liver graft remains speculative. The relation of Treg proportion 
and the development of acute rejection requires further analysis. 
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CHAPTER 8
Intrahepatic detection of Foxp3 gene expression after liver 
transplantation using minimally invasive aspiration biopsy
Ahmet Demirkiran, Carla C. Baan, Alice Kok, Herold J. Metselaar, 
Hugo W. Tilanus and Luc J.W. van der Laan
Transplantation 2007, 83, 819–823
ABSTRACT
Intragraft accumulation of Foxp3+ regulatory T cells (Treg) is associated with local suppres-
sion of allo-responses in transplantation models. In the current study the utility of the minimally 
invasive fine needle aspiration biopsy for the intragraft detection of Foxp3 and IFN-γ mRNA 
expression was investigated in clinical liver transplantation (LTx). Intragraft Foxp3 increased 
within the first year after LTx, but not in blood. Elevated Foxp3, but not IFN-γ expression, in 
the liver was observed after Hepatitis C virus (HCV) re-infection and after a previous episode 
of acute rejection. These data show the feasibility of aspiration biopsy for intragraft monitoring 
of gene expression. Intrahepatic Foxp3 levels are associated with HCV re-infection, a history 
of acute rejection and increased within the first year after LTx. Differences in gene expression 
between the graft and blood underline the importance of local immune monitoring.
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INTRODUCTION
Immune regulation is vital for maintenance of tolerance to self antigens (1-3) and non-self an-
tigens (4-6). Forkhead box P3 (Foxp3)-positive regulatory T cells (Treg) have been identified 
as important regulators in the immune homeostasis. Genetic defects, most notably Foxp3 
deficiency, or impaired activity of Treg have been associated with ineffective suppression 
of auto-reactive cells leading to the development of autoimmunity (7-10). Further evidence 
suggests that pathogens can exploit Treg to create a favorable immunological environment 
in order to escape an adequate immune response. For instance, in chronic viral infections in-
creased frequencies of circulating CD4+CD25+ T-cells have been reported (11-13). In chronic 
HCV infection, activation of virus-specific CD8+ T-cells is suppressed by CD4+CD25+ Treg and 
this may contribute to the inadequate immune response against the virus (14).
In experimental organ transplantation, CD4+CD25+ Treg can suppress anti-donor immune res-
ponses, thereby preventing the development of rejection (15-17). Recent data suggest that at 
least part of the suppressive activity of Treg occurs locally in the transplanted allograft (18). 
The suppression of T cells mediating graft rejection is an active process that involves the 
persistent presence of Treg at the site of the tolerated graft. Consistently, Foxp3 expression in 
tolerated skin, cardiac and liver allografts is significantly enriched compared to rejected grafts 
(19-21). In the clinical setting, Li et al have shown that Foxp3 expression in tolerant liver grafts 
predominates over markers of immune activation (22). In heart allografts, Foxp3 expression is 
increased during acute rejection (23). 
Here, we used the safe and minimally invasive biopsy technique, the Fine Needle Aspiration 
Biopsy (FNAB), to obtain liver tissue for the analysis of Foxp3 expression after human liver 
transplantation (LTx). Previously the FNAB has been successfully introduced for the detection 
of allograft rejection and liver inflammation (24-29), but no report has been made for the de-
tection of  intrahepatic gene expression in LTx. 
PATIENTS AND METHODS
Patients who underwent orthotopic LTx between June 2004 and July 2005 were consecutively 
enrolled. Recipient characteristics are summarized in Table 1. Immunosuppressive therapy 
consisted of anti-CD25 mAb (Basiliximab) induction therapy (i.v. 20 mg at day 0 and day 
4 post-Tx), a calcineurin inhibitior (Cyclosporin A or Tacrolimus) and steroids. Steroid treat-
ment with prednisone started with 20 mg daily from day 0 and was gradually weaned. Acute 
rejections all occurred within three months after LTx and were histologically diagnosed in 
liver biopsies according to the Banff classification criteria (1997). This study was approved 
by the Medical Ethical Committee of the Erasmus MC and an appropriate informed consent 
was obtained from all patients. Ultrasound guided FNAB specimens were obtained from the 
liver allograft of twenty liver transplant recipients at six and/or twelve months after LTx, as 
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Maintenance
Therapy
FNAB ALT (U/L)
Patient Sex Age Diseasea Acute
Rejection
CNIb Steroidsc 6 M 12 M 6 M 12 M
1 M 59 CLC - TAC - X 33
2 V 33 PSC - TAC + X 12
3 M 47 CLC - CsA + X 29
4 M 44 HCV - TAC + X X 126 194
5 M 41 CLC - TAC + X X 30 29
6 M 57 HBV - TAC - X 44
7 M 50 HCV - TAC - X 250
8 M 25 ALF + TAC + X 11
9 M 56 PSC - CsA + X 18
10 M 55 ALC - CsA + X 36
11 M 58 PBC - TAC - X 31
12 M 48 HCV - TAC - X X 102 171
13 V 38 PSC - TAC + X X 20 15
14 M 29 PSC + TAC - X 150
15 M 47 HCV + TAC - X 107
16 M 49 HCV - TAC - X 51
17 M 60 ALC - TAC + X 21
18 M 58 HBV + TAC + X 56
19 V 50 PBC - TAC + X 19
20 V 22 ALF - TAC - X 25
Tabel 1. Patient characteristics. a CLC Cryptogenic Liver Cirrhosis, PSC Primary Sclerosing Cholangitis, HCV 
Hepatitis C Virus Infection, HBV Hepatitis B Virus Infection, ALF Acute Liver Failure, ALC Alcholic Liver Cirrhosis, 
PBC Primary Biliary Cirrhosis, b CNI Calcineurin Inhibitor, TAC Tacrolimus, CsA Cyclosporin A, c + prednisone (5-10 
mg/day) use at time of FNAB, - no steroid use at time of FNAB. Hepatitis B virus (HBV) infected recipients (n=2) 
were additionally treated with anti-HBV immunoglobulines and lamivudine to prevent re-infection of the liver graft. 
HCV-positive recipients (n=5) did not receive any anti-viral therapy. 
previously described (30). From four patients paired (six and twelve month) samples were 
obtained. When the aspirate contained predominantly blood at macroscopic evaluation, an 
additional FNAB was taken. 
Only representative FNAB, i.e. containing at least seven hepatocytes per 100 leukocytes in 
cytospins, were included (25). Blood was collected at the time of the FNAB and peripheral 
blood mononuclear cells (PBMC) were obtained by density gradient centrifugation. Erythro-
cytes were lysed from PBMC (1 x 106 cells) and FNAB with a hypotonic buffer. Under these 
conditions the majority of hepatocytes (70-90%) in the FNAB were lysed. The remaining leu-
kocyte fraction was suspended in 0.5 ml TRIzol reagent (Life Technologies, GmbH, Karlsruhe, 
Germany) and 20 µg poly A (Boehringer, Mannheim, Germany) was added. The TRIzol ly-
C
ha
pt
er
 8
114
sates were directly stored at -80ºC. Total RNA was extracted with 160 μl of cold chloroform-
isoamylalcohol and subsequently precipitated with ice-cold 80% ethanol (350 µl). The precipi-
tated solution was then loaded on a RNA-isolation column from the Qiagen RNeasy isolation 
kit (Qiagen, Venlo, The Netherlands) and RNA was isolated according to the manufacturer’s 
instructions. Total RNA was denaturated for 10 min at 80°C and then chilled to 4°C. First-
strand cDNA synthesis was performed as previously described (31). Real-time RT-PCR was 
used to quantify Foxp3 , IFN-γ mRNA and as reference genes the constant region of the T cell 
receptor α chain (TCR-Cα) and CD3ε. Primers and probes for Foxp3, IFN-γ and CD3ε were 
obtained from Applied Biosystems (Foster City, CA, USA). The used sequences for TCR-Cα 
transcripts were as previously described (23). Amplifications were performed using the ABI 
7700 sequence detector system (Applied Biosystems).
RESULTS AND DISCUSSION
None of the twenty liver transplant recipients experienced complications due to the FNAB. 
When comparing FNAB taken at six or twelve months after LTx, Foxp3 expression significantly 
increased in the liver, while relative expression in peripheral blood did not significantly change 
(Figure 1). The relative increase of Foxp3 was confirmed in four individual patients with paired 
FNAB samples taken at six and twelve months (median Foxp3 level of 47 at six- versus 128 
at twelve-months). When CD3ε mRNA was used as a reference (n=15), the increase of Foxp3 
levels in the graft at 12 months (p=0.045) was confirmed. No significant differences in liver 
or blood were seen for expression of IFN-γ related to TCR-Cα or CD3ε (not shown). The ob-
served increase of Foxp3 expression could indicate that Foxp3+ cells of the recipient traffic 
Figure 1. Intrahepatic enrichment of Foxp3 expression in time after transplantation. Analyzes of mRNA was performed by 
RT-PCR of liver FNAB and PBMC at six- (n=11 and 10, respectively) and 12-months (n=12) post-LTx. mRNA was quantified 
by measuring threshold cycle (Ct). ( A ) Relative to TCR-Cα Foxp3 mRNA levels in the liver were increased at 12 months 
after LTx compared to 6 months. ( B ) Levels in blood showed no significant difference for Foxp3 mRNA at these time points. 
The increase of Foxp3 in the liver was confirmed in a subset of samples with CD3ε as T-cell specific reference gene (n=15, 
p=0.045, not shown). The bar indicates median. Statistical analysis was performed with the Wilcoxon paired test (SPSS 
version 11.5, Chicago, IL). 
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Figure 2. Increased intrahepatic Foxp3 levels after HCV re-infection and acute rejection. Comparison of mRNA expression 
in HCV-positive (n=7), resolved acute rejection (n=3) and non-HCV/non-rejection FNAB (n=13). ( A ) Relative Foxp3 expres-
sion in the liver at was significantly higher in HCV recipients and in patients with a history of acute rejection as compared to 
non-HCV and non-rejectors. The increased Foxp3 in the liver of HCV recipients was confirmed in a subset of samples where 
CD3 could be determined as an additional T-cell reference gene (p<0.025). ( B ) In peripheral blood Foxp3 expression was 
not different between the groups. 
into the graft and accumulate within time after LTx. However, whether the increase in Foxp3 
expression represents a tolerant state of the liver graft, remains speculative.
To investigate the effect of HCV recurrence on Foxp3 gene expression, we compared HCV-
positive and -negative recipients. All five HCV positive recipients developed recurrence of 
disease as indicated by biopsy histology and high viral load (range 1.15-2.68x107 geq/ml). 
Serum AST levels were elevated in most of these patients, indicating active liver disease 
(Table 1). As shown in Figure 2A, in FNAB of HCV-positive recipients Foxp3 expression was 
significantly increased compared to non-HCV recipients. In blood no significant differences 
were detected (Figure 2B).  The increased Foxp3 in the liver was confirmed in a subset of 
samples where CD3ε could be determined as an additional T-cell reference gene (p<0.025) 
and no such differences were seen in blood (not shown). The relative expression of IFN-γ in 
liver and blood was not different between HCV and non-HCV recipients (Figure 2C and D). 
It is known that HCV employs different strategies to evade an adequate immune response. 
One of these immunological escape mechanisms that has been reported is the induction 
of virus-specific Treg. Increased levels of these cells were shown to suppress HCV-specific 
CD8+ T cells (32, 33). Our data, showing an increased expression of Foxp3 in liver grafts from 
HCV positive recipients, suggest an intrahepatic enrichment of Treg (Figure 2). The presence 
of Foxp3+ Treg in liver FNABs was recently confirmed by flowcytometric analysis in chronically 
HCV patients in our laboratory (Claassen et al. unpublished data).
The impact of an acute rejection episode on Treg-associated gene expression at 6 and 12 
months post-LTx was determined in liver and blood. Three of fifteen non-HCV recipients pa-
tients experienced an episode of biopsy-proven (RAI≥5) acute rejection, which resolved spon-
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taneously. As shown in Figure 2A, relative Foxp3 levels in the liver of rejectors were signifi-
cantly higher compared to non-rejectors, while levels in blood were comparable. IFN-γ mRNA 
expression was not different in liver or blood (Figure 2C and D).
Acute allograft rejection episodes are characterized by an influx of donor-reactive T cells 
within the graft. This is accompanied by a prominent increase in mRNA of pro-inflammatory 
cytokines, such as IL-2 and IFN-γ (34, 35). Baan et al showed that during a rejection episode 
of cardiac allografts relative expression of Foxp3 increased (23). This could indicate an influx 
or local induction of Foxp3+ T cells in the transplanted organ during rejection. Our results 
for LTx, indicate an increased Foxp3 mRNA long after the occurrence of a spontaneously 
resolved rejection episode (Figure 2). At this time-point the IFN-γ mRNA was not elevated. 
Whether this high Foxp3 expression is associated with a more immune tolerogenic status or 
associated with immune activation remains to be determined. Interestingly, a recent study in 
kidney transplant recipients suggests that levels of Foxp3 mRNA may serve as a mechanis-
tically informative biomarker of acute-rejection outcome, with lower levels associated with 
irreversible acute rejection and even graft failure (36). Though statistically significant differen-
ces were observed in our study, the overlap of Foxp3 expression between the controls, HCV 
positive recipients and resolved acute rejectors currently limits the use of intragraft Foxp3 as 
a clinically relevant biomarker in LTx.
In summary this study demonstrates that FNAB can be used to monitor gene expression 
profiles in the liver allograft. Using aspiration biopsy it is possible to safely and frequently 
sample the graft. The diameter of this needle is significantly smaller than the classical needle 
and therefore does not require anesthetics and has minimal risk of serious complications. The 
differences between peripheral blood and the liver highlight the importance of local immune 
monitoring, which may be important for the detection of transplant tolerance. 
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Part IV
Closure

CHAPTER 9
Summary and Discussion
Ahmet Demirkiran

The success of solid-organ transplantation depends on the continuous administration of im-
munosuppressive drugs to prevent rejection. Most of the currently used immunosuppressive 
drugs, however, are toxic and target the immune response in a nonspecific fashion. Life long 
use of immunosuppressive drugs is accompanied by many debilitating side effects influencing 
long-term graft and patient survival and quality of life. Therefore, reducing the necessity of im-
munosuppressive drugs by inducing transplant tolerance is the ultimate challenge in the organ 
transplantation field. One of the possibilities to achieve a state of tolerance is to exploit regu-
latory T cells (Treg). In various experimental transplantation models Treg have been shown 
to play a vital role in tolerance (1-3). Although several subsets of Treg have been described 
to play a role in transplant tolerance, the CD4+CD25+Foxp3+ Treg appear to play a prominent 
role in controlling the allo-response after transplantation. This subset is capable to induce and 
maintain immunological non-responsiveness, also referred to as operational tolerance. Howe-
ver, this does not exclude a possible role for other significant regulatory populations, like IL-10 
producing Tr1 cells (4), CD8+ suppressor T cells (5) and NKT cells (6), in clinical transplant 
tolerance. As a matter of fact, these distinct regulatory cell populations may all be involved in 
the immunological outcomes following transplantation, individually or synergistically. In this 
thesis we focused on the CD4+CD25+Foxp3+ Treg subset.
The induction of donor-specific Tregs and the potential use of these cells in transplantation 
tolerance is one of the main topics of research in transplantation immunology. The nonspecific 
inhibition of the immune system by immunosuppressive drugs may impact the development 
and function of these Treg and therefore the effect of immunosuppressive drugs on Treg 
should be made clear to optimize tolerance induction strategies. In chapter two we reviewed 
recent knowledge on the effect of immunosuppressive medication on the homeostasis and 
function of Treg in vitro and in clinical transplantation. 
Circulating regulatory T cells
In part II of this thesis we investigated Treg levels in relation to immunosuppressive therapy, 
to the occurrence of acute rejection and to time after liver transplantation. Our data suggest 
that immunosuppressive therapy, in particular the combinational use of steroids and calcineu-
rin inhibitors (CNI), reduce the numbers of CD4+CD25+ Treg in peripheral blood. This finding 
highlights the possible contrasting effects of immunosuppression: preventing acute rejection 
by blocking the activation of effector T cells, but also possibly inhibiting the development of 
donor-specific tolerance by suppressing Treg. In chapter three and chapter four we showed 
that after human liver transplantation the percentage of Treg expressing CD4, CD25, CD45RO 
and CTLA-4, changes dramatically. Levels of these Treg in peripheral blood decreased after 
transplantation. Importantly, we found significant differences in Treg levels between patients 
who experienced acute rejection versus non-rejectors. Despite these quantitative changes, 
the suppressive activity of isolated CD4+CD25+ T cells from liver transplant recipients, both 
rejectors and non-rejectors, was comparable to that of healthy controls. Furthermore, we  sho-
wed an association between steroid treatment for acute rejection and sustained low levels of 
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Treg, which illustrates the effect of immunosuppression on Treg. Taken together, these data 
imply that immunosuppressive therapy effects Treg levels in blood and that upon allogeneic 
stimulation the suppressive capacity of total Treg may affect the course of immune activation 
causing rejection or non-responsiveness. 
The suggested negative effect of CNI on Treg was confirmed in chapter five showing a sig-
nificant increase of Foxp3+ cells within the CD3+CD4+ T cells after discontinuation of CNI and 
a decrease after re-introduction of CNI. We conducted a conversion study in long term liver 
transplant recipients with renal impairment. To study the effect of CNI conversion on Treg 
and to improve renal function we changed the immunosuppressive therapy from CNI to my-
cophenolate mofetil (MMF). We observed that conversion to MMF caused the percentage of 
Foxp3+ cells to increase after six months as well as an increase of CD25 expression on Foxp3+ 
cells suggesting that Treg may become more susceptible to IL-2 signals. These findings are in 
line with previous studies showing a decrease of Treg after CNI treatment and higher levels of 
Treg in patients treated with a non-CNI based immunosuppressive regimen (7-10). The pos-
sible negative effect of CNI on tolerance is accompanied with non-immunological side effects, 
in particular nephrotoxicity, causing significant morbidity. This study showed that conversion 
from a CNI based immunosuppressive regimen to MMF monotherapy improves renal function 
with a low risk of acute rejection, supporting previous conversion studies in liver transplant 
recipients. Conversion from CNI to MMF in liver transplant recipients increases the proporti-
ons of circulating CD4+CD25bright T cells, CD4+CD25+CTLA-4+ T cells and CD4+Foxp3+ Treg, 
which may have important implications on graft immunity and tolerance. Clinically, conversion 
results in an improvement of renal function and a decrease of blood pressure. 
Intrahepatic regulatory T cells
In part III we aimed to study the presence of Treg within the donor liver before and after 
transplantation. The unique immunological properties of the liver have partly been attributed 
to the resident leukocyte population. Following liver transplantation, donor leukocytes present 
in the graft are transferred and persist in recipients, a condition referred to as chimerism. In 
chapter six we investigated the presence of Treg in the liver graft by analysis of the perfu-
sion solution obtained prior to transplantation. We also studied the presence of donor Treg in 
recipient blood after transplantation. Within perfusate helper T cells, an increased proportion 
of CD25+CTLA-4+ and CD25+Foxp3+ T cells were found as compared to peripheral blood of 
healthy controls. We confirmed the presence of Treg by analysis of Foxp3 mRNA expression 
in liver perfusate mononuclear cells. Furthermore, we demonstrated that donor leukocytes 
detaching from the liver were present in recipient circulation and contained substantial num-
bers of donor CD4+CD25+CTLA-4+ T cells. In a mixed leukocyte reaction we were able to 
show that donor Treg could suppress the direct pathway alloresponse as shown by inhibition 
of proliferation and cytokine production of recipient-responder T cells upon stimulation with 
donor cells. This observation suggests that Treg can suppress across a MHC barrier. These 
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data indicate that chimerism of donor Treg may contribute to suppression of the direct pa-
thway alloresponse that is the dominant antigen presentation pathway driving rejection early 
after transplantation. Donor leukocyte migration and chimerism are associated with transplant 
tolerance both in the clinical and experimental setting. Depletion of donor leukocytes or failure 
to develop chimerism was shown to result in prompt rejection (11-13), but chimerism by itself 
is not sufficient to prevent rejection. In clinical transplantation, the beneficial effect of donor 
leukocytes was clearly shown by pre-transplant donor blood transfusions leading to enhanced 
graft survival (14, 15). It is evident that donor leukocytes are important during the first weeks 
after transplantation, in which maximal donor migration and interaction with host leukocytes 
occur (16). The exact mechanism in achieving tolerance through chimerism, however, has not 
been elucidated. Whether graft-derived donor Treg influence the balance between the immu-
nogenicity and tolerogenicity of organ allografts remains to be determined. We have shown 
that donor Treg are functional in suppressing the direct pathway allo-responses in vitro and 
may therefore contribute to chimerism-associated tolerance early after liver transplantation.
In chapter seven and chapter eight we studied the expression profiles of immune activating 
and immune suppressive cytokine genes as well as Treg associated genes. We also per-
formed a flowcytometric analysis of leukocytes present in the liver. To obtain liver tissue we 
chose the fine-needle aspiration biopsy technique, which has been shown to be a minimally 
invasive procedure enabling us to study intrahepatic parameters. In chapter seven we aimed 
to study the changes of Treg associated gene expression and several cytokine genes early 
after transplantation. We presented preliminary data on the early presence of Treg within the 
graft and cytokine expression profiles in relation to the occurrence of acute rejection. This stu-
dy showed that acute rejection is associated with reduced RNA expression levels of the immu-
nosuppressive cytokine IL-10 in the liver and in blood. In the early phase after transplantation 
there was a higher IFN-γ expression, while at later time points IL-10 expression remained high 
in the liver and IFN-γ expression levels were not different from blood. This suggests that in the 
first weeks after transplantation immune activating genes predominate, followed by immune 
suppressive gene expression at 6 and 12 months after transplantation. Differences in IL-10 
expression and possibly Foxp3+ and Foxp3- T cell ratio may have a predictive value for the 
development of acute rejection. Moreover, cytokine expression/production patterns may effect 
the immunological course leading to graft acceptance or rejection. The observed differences 
in the limited numbers of patients highlight the importance of early immune profiling. Further 
study and expansion of the study group is required to understand the clinical relevance of 
these findings. Important issues remaining to be answered are the origin of the different ex-
pressed cytokines and the relationship of Treg with other cells present in the liver.
In chapter eight we demonstrated that one year after transplantation Foxp3 expression signi-
ficantly increased in the liver compared to six months, while relative expression in peripheral 
blood did not significantly change. This observed increase of Foxp3 expression could reflect 
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an intrahepatic accumulation of Foxp3+ cells within time after liver transplantation. Whether 
the increase in Foxp3 expression represents a tolerant state of the liver graft, remains specu-
lative. Interestingly, we observed differential expression of Foxp3 between Hepatitis C Virus 
(HCV)-positive and -negative transplant recipients. In HCV-positive recipients Foxp3 expres-
sion in the liver, but not in blood, was significantly increased compared to non-HCV recipients. 
This finding suggests an intrahepatic enrichment or activity of Treg. HCV is thought to persist 
and escape an adequate immune response by manipulating the host immune system. One of 
the immunological escape mechanisms of HCV to avoid an adequate immune response that 
has been reported is the induction of virus-specific Treg. Increased levels of Treg were shown 
to suppress a specific anti-HCV T cell response. The increased levels of Foxp3 expression 
within the liver may reflect a more tolerogenic environment towards the virus. Further charac-
terization of intrahepatic Treg may advance our understanding of HCV recurrence and persi-
stence, which could be used for the enhancement of anti-HCV immune response/therapy. 
An episode of biopsy-proven (RAI≥5) acute rejection was associated with increased Foxp3 
levels in the liver compared to non-rejection, while levels in blood were comparable. Acute 
allograft rejection episodes are characterized by an influx of donor-reactive T cells within the 
graft. This is accompanied by a prominent increase in mRNA of pro-inflammatory cytokines, 
such as IL-2 and IFN-γ. Our results indicate an increased Foxp3 mRNA long after the occur-
rence of a spontaneously resolved rejection episode. At this time-point the IFN-γ mRNA was 
not elevated. Whether this high Foxp3 expression is associated with a more immune tolero-
genic status or associated with immune activation remains to be determined. The aspiration 
biopsy, as an alternative to classical needle-biopsy, has been shown to be safe and to be utile 
to monitor gene expression profiles in the liver allograft. The differences between peripheral 
blood and the liver underline the importance of local immune monitoring, which may have 
important implications of our understanding of rejection and transplant tolerance. 
  
The ability to accurately quantify anti-donor immunity is an important issue in clinical trans-
plantation. The ultimate aim is to enable identification of transplant recipients who can be 
weaned from immunosuppressive therapy based on immuno-assays in order to raise the 
quality of life and improve transplantation outcome. Several mechanisms of tolerance and 
tolerance induction have been suggested including active immune regulation, chimerism, T-
cell and B-cell deletion, anergy and clonal exhaustion. All of these mechanisms may repre-
sent one of the “ways to Rome”, however, up to date evidence to link these mechanisms are 
lacking and require further exploration to fully understand their role in clinical transplantation. 
Most of these mechanisms have been studied in an experimental setting and need further 
analysis in the clinic. We aimed to identify and study changes of Treg in clinical liver trans-
plantation. In this thesis we have shown that functionally active Treg are present in the liver 
and in the circulation of liver transplant recipients. The choice of immunosuppressive therapy 
has been shown to influence the fate of these cells, thereby interfering with the natural ho-
meostatic regulatory status and possibly tolerance induction. This reflects the two edges of 
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the immunosuppressive sword; preventing rejection on one hand, but also inhibiting tolerance 
mechanisms on the other hand. 
Future Perspectives
Longstanding evidence shows that a subset of liver transplant recipients is tolerant for the graft 
and theoretically does not require any immunosuppression. In addition, a substantial number 
of patients is thought to be over-immunosuppressed. Lerut et al. elegantly summarized the 
several studies showing liver transplant tolerance (17). Safe adjustments and weaning of 
immunosuppression without rejection requires prognostic tests that identify patients who are 
hypo-responsive or even tolerant for their graft. Currently, no such tests exist to differentiate 
between tolerant and non-tolerant patients. Hence, to improve long-term transplant outcome, 
several major challenges remain, including detection of transplant tolerance based on diag-
nostic tests and minimizing the level of immunosuppression to prevent side effects. 
The development of tolerance assays and the implementation of clinical tolerance trials are 
closely dependent upon each other. Introduction of tolerance induction protocols in organ 
transplantation will require the identification of simple, robust, ideally non-invasive biological 
markers reflecting the immune allo-reactivity of the recipient towards his/her donor graft. In 
the past decades much progress has been made in understanding how the immune system 
is regulated, with a great deal of recent interest in CD4+ Treg that actively engage in the 
maintenance of immunological self-tolerance and immune homeostasis (1, 18). Therefore 
it is tempting to use Treg as a possible marker. In order to do so, complete dissection of 
the molecular framework and cellular processes concerning the development and function of 
Treg is a must. Once accomplished, exciting possibilities may emerge for the manipulation of 
regulatory T-cell pathways in controlling anti-donor immune responses. The identification of 
the transcription factor forkhead box p3 (Foxp3) as being the master transcription factor, regu-
lating Treg development and function, has made it possible to further characterize these cells 
(19, 20). A key question that has emerged from these findings is how Foxp3 orchestrates the 
cellular and molecular programs involved in Treg function. Recent studies have shown that 
Foxp3 binds to other transcription factors such as NFAT (nuclear factor of activated T cells), 
thereby interfering with the transcription of the gene encoding for IL-2 (21, 22). Furthermore, 
Foxp3 up-regulates the expression of CD25 and other Treg cell–associated molecules. As 
shown in this thesis, current immunosuppressive agents have an effect on these pathways 
and may therefore disturb the natural pathway of tolerance induction. Further confirmation and 
specification of these findings in experimental models will provide major insight on the effects 
of immune suppressive therapy on tolerance. Changes in immunological status after single 
immune suppressive therapy and in combination, as used in the clinic, need further investiga-
tion to determine the optimal strategy without interfering with the induction of tolerance.
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Understanding of the distinct effects of immunosuppression on Treg and tolerance is required 
to be able to adjust or chose the optimal immunosuppressive strategy. Further analysis in in 
vivo models is necessary to fully understand the impact of different immunosuppressive stra-
tegies on tolerance. One possibility is to set up an experimental liver transplantation model 
and investigate the effect of immunosuppression on Treg in relation to naturally developing 
tolerance. This setup will also allow studying the effect of Treg on other cell subsets in vivo in 
relation to tolerance. Up to date most studies performed on Treg are based on in vitro models, 
which may not adequately reflect in vivo Treg activity. We do know now that Foxp3+ Treg can 
both directly and indirectly suppress the activation and proliferation of many cell types inclu-
ding T cells, B cells, Dendritic Cells, Natural Killer cells and Natural Killer T cells (23, 24). All of 
these cells are known to be present in the liver. These important findings suggest that Foxp3+ 
Treg cells do not suppress immune responses by a single mechanism, but may exploit various 
pathways in a context-dependent manner. In addition, another key challenge remaining in the 
understanding of Treg mediated tolerance is the elucidation of the exact mechanism of sup-
pression by Treg. So far, it is established that cell-cell contact is mandatory, but the position of 
immunosuppressive cytokines, like IL-10 and TGF-β, remains controversial (25-27). Several 
membrane-bound components have been identified as possible candidates involved in the 
cell-to-cell interaction between Treg and effector cells. CTLA-4, a co-inhibitory molecule, was 
shown to be highly expressed in Treg and is functional in Treg-mediated suppression (23, 28). 
Other candidates, such as membrane-bound TGF-β (29) and GITR (30), have also been sug-
gested, but conclusive evidence is still lacking (31, 32). In sum, clarification on the interactions 
between Treg and other cell types involved in the allogenic immune response and the effect 
of immunosuppression on these interactions is necessitated. 
An important issue raised in the past years is the actual site in which Treg are functional. Ana-
lysis of circulating Treg has been very informative on the proportions and functionality of these 
cells, however, whether the circulating pool of Treg reflects the actual pool of Treg involved in 
the anti-donor immune response remains unknown. The major limitation of most studies is the 
analysis of Treg present in peripheral blood, which might not mirror the condition inside the 
transplanted organ and the lymphoid tissue. In the clinical setting it is nearly impossible to ob-
tain lympoid tissue, which is a major hurdle in Treg research. In animal models the presence of 
these cells in the graft was linked to the development of acute rejection, suggesting local sup-
pression within the graft. Using fine-needle-aspiration biopsy it is now possible to easily obtain 
liver tissue and study intragraft cells and gene expression. The possibility to analyze gene 
expression patterns with gene array chips holds great promise for discovering non-invasive 
biomarkers for monitoring of intragraft events. Therefore, micro-array analysis should be the 
next step in the intragraft analysis following transplantation. Differences of immune parame-
ters in the transplanted organ and in blood, as shown in this thesis, highlight the importance of 
analyzing multiple aspects and behaviours of the immune system. The combination of careful 
immune monitoring and intragraft assessment of immunological events may hold the key to 
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detect tolerant patients. Recent advances in our understanding of the molecular mechanisms 
that control the development of Treg cells have provided new avenues of investigation, but key 
questions concerning the antigen specificity of Treg cells, their homeostasis, and mechanism 
of action remain.
The liver is known for its unique immune privilege and in transplantation setting is more often 
tolerated compared to other organs, reflected by lower rejection rates and dosage of immuno-
suppressive drugs. The tolerogenic environment of the liver is well illustrated by several infec-
tious diseases, such as Malaria and hepatitis inducing viruses, which often result in chronic 
infections. The resident immune cells in the liver are thought to play a crucial role in the liver’s 
immune privilege. For this, the structural organization of the liver is thought to be essential. Lar-
ge populations of resident leukocytes are present in the liver, which differ from those in blood. 
These cells are distributed through the sinusoidal spaces and are also organized in lymphoid 
aggregates in the portal tracts, allowing close cell-cell interactions. Antigen presenting cells 
are abundantly present in the liver and include Kupffer cells, liver sinusoidal endothelial cells 
(LSEC) and dendritic cells, which phenotypically and functionally differ from those in blood. The 
dendritic cells are predominantly immature and are prone to capture and process antigens. In-
terestingly, immature dendritic cells have been shown to have tolerogenic properties, including 
the ability to induce Treg (33, 34). High IL-10 and TGF-β expression by Kupffer cells and LSEC 
are thought to create a unique cytokine micro-environment that may render resident dendritic 
cells tolerogenic (35-37). Therefore, it is essential to identify tissue-specific factors that influ-
ence the balance between Treg and effector T cells in distinct tissue sites and to understand 
the bi-directional interactions of the different cells types present in the liver in order to envision 
the exact processes involved in tolerance. Selective depletion of the different cell types in a 
liver transplantation model may provide us the specific roles of the different cell populations in 
tolerance induction. This knowledge can then be implemented in a strategy to manipulate the 
immune system causing transplant tolerance.  
From a clinical perspective, the assessment of allo-reactivity using immunological monitoring 
in transplant recipient may be directed at the following aims: (1) early, non-invasive detection 
of allograft rejection, (2) determination of the level of immunosuppression required (choice 
of immunosuppression, dosage adjustment) and (3) analysis of the immunological phenotype 
related to operational tolerance and safe immunosuppression withdrawal in a subgroup of re-
cipients. Essential for this is an adequate approach in a multidisciplinary fashion requiring ap-
propriate interactions between clinicians and immunologists, which should ideally be organized 
in a prospective fashion from the time of transplantation. Eventually, with innovations in the 
detection of both reactive- and regulatory-cells we will get a better insight into the immune 
status of transplant recipients. Accurate visualisation of the host immune reactivity will allow us 
to stratify patients towards more tailor-made immunosuppressive regimens, thereby improving 
long term survival and quality of life .
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CHAPTER 10
Dutch Summary (Samenvatting)

Levertransplantatie is de behandeling bij uitstek wanneer het eindstadium van leverziekte is 
bereikt. Na transplantatie wordt het donor orgaan door het immuun systeem van de ontvan-
ger als niet-eigen herkend en ontstaat er een afstotingsreactie. Ter preventie van afstoting 
krijgen alle patiënten die een transplantatie ondergaan levenslang afweeronderdrukkende 
medicatie (immunosuppressiva) voorgeschreven. Echter, immunosuppressiva onderdrukken 
de algehele afweer op een niet specifieke manier, waardoor de ontvangers extra gevoelig zijn 
voor bacteriële, virale en schimmelinfecties en voor het ontwikkelen van kanker. Nierfalen, 
botontkalking en hart- en vaatziekten behoren tot de meest voorkomende bijwerkingen. In 
de huidige Rotterdamse patiëntenpopulatie kampt ongeveer tweederde van de patiënten na 
transplantatie met de bijwerkingen van de toegepaste immunosuppressiva.
Na onttrekking van immunosuppressiva aan transplantatie patiënten die al jaren een sta-
biele transplantaatfunctie hebben, blijkt zich in een deel van de betrokkenen geen afstoting 
te ontwikkelen. Het is onbekend waarom bij sommige patiënten blijkbaar tolerantie voor het 
transplantaat optreedt, terwijl bij anderen immunosuppressiva niet onttrokken kunnen worden 
zonder dat dit tot afstoting leidt. Wel is bekend dat tolerantie vaker optreedt na levertransplan-
tatie in vergelijking met andere organen. Het verminderen of zelfs stoppen van de immuno-
suppressieve medicatie zou leiden tot een belangrijke reductie van de morbiditeit en daardoor 
ook mortaliteit na transplantatie. Momenteel is het echter niet mogelijk om te bepalen welke 
patiënt wel of geen immunosuppressiva hoeft te gebruiken.
Onderzoek in diermodellen heeft aangetoond dat regulatie een cruciaal element is voor het 
bereiken van tolerantie. Aangetoond is dat een speciale subset van witte bloedcellen, ge-
naamd regulatoire T-cellen, een belangrijke rol spelen bij transplantaat tolerantie. Deze re-
gulatoire cellen zijn in staat om de functies van reactieve T-cellen, die de afstotingsreactie in 
gang zetten, te remmen.
Het eerste gedeelte van dit proefschrift (Part I) omvat een korte introductie, het doel en de op-
zet van dit proefschrift (hoofdstuk 1). In hoofdstuk 2 is er een literatuuroverzicht beschreven 
over de effecten van afweeronderdrukkende medicatie (immunosuppressiva) op regulatoire 
T-cellen in klinische orgaan transplantatie. De rol van deze regulatoire T-cellen in het induce-
ren en in stand houden van transplantaat tolerantie in experimentele diermodellen heeft vele 
onderzoekers gestimuleerd om onderzoek te doen op dit gebied. Een van de belangrijkste 
werkingsmechanismen van de huidige immunosuppressiva is het remmen van reactieve T-
cellen, die onder andere betrokken zijn bij de afstotingsreactie, te remmen. Als onderdeel van 
de helper T-cel populatie is het dus mogelijk dat immunosuppressiva ook een remmend effect 
hebben op regulatoire T-cellen, en dit zou kunnen resulteren in een ongewenste remming 
van transplantaat tolerantie. In verschillende diermodellen is reeds aangetoond dat onder 
andere het toedienen van calcineurine remmers (Cyclosporine A en Tacrolimus), een van de 
meest gebruikte immunosuppressiva, juist een negatief effect hebben op tolerantie en dat 
het transplantaat werd afgestoten na het staken van de immunosuppressiva. Een van de 
hypothetische verklaringen voor dit fenomeen is het remmende effect van calcineurine rem-
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mers op regulatoire T-cellen. De recente literatuur toont verschillende effecten op de functie 
en overleving van regulatoire T-cellen bij de verschillende immunosuppressiva die gebruikt 
worden. Met name blijken de calcineurine remmers de verhouding tussen regulerende en 
reactieve T-cellen te veranderen. Dit is een belangrijke bevinding en kan van invloed zijn op 
de keuze en mate van immunosuppressieve medicatie in de toekomst. Hiervoor dienen de 
specifieke effecten van immunosuppressiva nader onderzocht te worden, met name het effect 
op regulatoire cellen. Uiteindelijk kan dit leiden tot geïndividualiseerde immunosuppressieve 
behandeling en in een deel tot compleet stoppen, waardoor de kans op complicaties van de 
behandeling aanzienlijk zal worden gereduceerd. 
In het tweede gedeelte van dit proefschrift (Part II) worden regulatoire T-cellen in de bloedcir-
culatie gekarakteriseerd en de effecten van verschillende immunosuppressieve behandeling 
op de cellen beschreven. In hoofdstuk 3 en 4 hebben wij laten zien dat patiënten met een 
eindstadium leverziekte verhoudingsgewijs meer regulatoire T-cellen in het bloed hebben en 
dat na een levertransplantatie het aantal significant daalt. Er is daarbij een associatie gecon-
stateerd tussen immunosuppressiva gebruik en de daling van het aantal regulatoire T-cellen. 
Alle patiënten in deze studie kregen immuunsuppressie op basis van calcineurine-remmers, 
maar dat is nog geen bewijs dat deze medicatie verantwoordelijk was voor de daling. Ech-
ter, duidelijk bleken patiënten die een acute afstotingsreactie hadden ontwikkeld en daarvoor 
werden behandeld met steroïden, significant minder regulatoire T-cellen te hebben. Deze 
bevindingen hebben wij nader willen onderzoeken in een prospectief onderzoek (hoofdstuk 
5) waarbij patiënten die een calcineurine remmer gebruikten werden geconverteerd naar een 
ander type immunosuppressivum, mycophenolaat mofetil. Gedurende zes tot negen maanden 
werd van deze patiënten bloed afgenomen om het effect van de conversie te onderzoeken. 
Na het stoppen van de calcineurine remmer steeg het percentage regulatoire T-cellen van het 
totaal aantal T-cellen, bevestigd middels een verhoogd Foxp3 genexpressie. Daarbij waren er 
tevens fenotypische veranderingen van de regulatoire T-cellen, onder andere een verhoogd 
IL-2 receptor expressie. Een belangrijke klinische observatie in deze studie was dat er een 
significante verbetering van de nierfunctie was opgetreden. Twee patiënten ontwikkelden een 
afstotingsreactie die adequaat behandeld konden worden met steroïden. Geen van deze ver-
anderingen werden gezien in de controle patiënten, die de calcineurine remmer behandeling 
hebben gecontinueerd. Concluderend blijken er duidelijke verschillende effecten te bestaan 
van de verschillende afweeronderdrukkende medicijnen op het immuunsysteem. Wij hebben 
in levertransplantatie patiënten functionele regulatoire T-cellen aangetoond die onder invloed 
van calcineurine remmers dalen in het bloed. In diermodellen zijn er nu sterke aanwijzingen 
dat de keuze van behandeling tolerantie negatief kan beïnvloeden. Het specifieke effect hier-
van op de anti-donor reactiviteit in de mens dient verder geanalyseerd te worden. 
In het derde gedeelte (Part III) wordt getracht meer inzicht te geven in de immunologische ka-
rakteristieken van de getransplanteerde lever. Hiervoor hebben we op verschillende tijdstippen 
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gekeken naar onder meer de aanwezigheid van regulatoire T-cellen in het levertransplantaat. 
Er zijn aanwijzingen dat de aanwezigheid van regulatoire T-cellen in het getransplanteerde or-
gaan een belangrijke rol spelen bij het reguleren van de immuun respons en tolerantie kunnen 
induceren. Dit suggereert dat de onderdrukking van de anti-donor reactiviteit door regulatoire 
T-cellen (deels) lokaal plaats vindt, dus in het getransplanteerde orgaan. Een ander bekend 
fenomeen wat een duidelijke link heeft met tolerantie is het optreden van chimerisme, gedefi-
nieerd als het persisteren van donor afkomstige immuun cellen in de ontvanger. In hoofdstuk 
6 hebben we perfusievloeistof van de donor lever opgevangen en geanalyseerd. Onder meer 
is er gekeken naar de samenstelling van de aanwezige immuun cellen, met name de aanwe-
zigheid van donor regulatoire T-cellen. Wij hebben aangetoond dat donor regulatoire T-cellen 
aanwezig zijn in perfusievloeistof en dat deze cellen na transplantatie vrij komen en circuleren 
in de ontvanger. Bovendien waren deze regulatoire cellen in staat om de anti-donor respons 
door de ontvanger cellen te remmen. Dit pleit voor de veronderstelling dat er een belangrijke 
rol is voor regulatoire T-cellen in chimerisme-geassocieerde tolerantie. De directe link tussen 
de aanwezigheid van donor regulatoire T-cellen in de lever en de uitkomst na transplantatie 
dient nader onderzocht te worden. 
Om op een veilige en patiënt vriendelijke wijze leverweefsel na transplantatie te verkrijgen 
hebben wij gekozen voor een alternatieve methode: de dunne-naald aspiratie biopsie. Om 
post-operatief de regulatoire T-cellen in de lever te kunnen monitoren hebben wij middels dun-
ne-naald-aspiratie leverweefsel verkregen en geanalyseerd. Deze techniek blijkt een goed al-
ternatief voor de klassieke dikke naald biopsie, die kan leiden tot ernstige complicaties. Doel-
stelling van deze studie was om beter inzicht te krijgen in de immunologische karakteristieken 
van de getransplanteerde lever. Hiervoor is er op een veilige en patiënt vriendelijke wijze 
leverweefsel middels dunne naald biopsie afgenomen van lever transplantatie patiënten in de 
eerste maand (hoofdstuk 7), op 6 maanden en 12 maanden (hoofdstuk 8) na transplantatie.
In de eerste weken na transplantatie blijkt er in vergelijking met het bloed een verhoogd lever 
expressie te zijn van IFN-γ, een T-cel activerend cytokine. Op 6 maanden na transplantatie 
is IFN-γ niet meer verschillend tussen lever en bloed (hoofdstuk 7). De verhoogde IFN-γ ex-
pressie ging gepaard met relatief meer regulatoire T-cellen in de lever vergeleken met bloed. 
Deze bevindingen impliceren een verhoogde mate van activiteit en regulatie vroeg na trans-
plantatie. Een interessante observatie was dat de expressie van het immuunsuppressieve 
cytokine IL-10 aanvankelijk niet verschillend is tussen lever en bloed in de eerste weken na 
transplantatie, maar op den duur wel degelijk verschillen toont op 6 en 12 maanden na trans-
plantatie. Dit suggereert een immuunsuppressief milieu in de lever die ontstaat na verloop van 
tijd. Vroeg na transplantatie blijkt er tijdens een acute afstotingsreactie een lager expressie te 
zijn van IL-10 in de lever en in bloed vergeleken met patiënten die geen afstotingsreactie ont-
wikkelden. Collega Dr. M.C. Warlé heeft in 2002 aangetoond dat polymorfismes van cytokine 
genen, waaronder het IL-10 gen, een genetische risicofactor kan zijn voor het ontwikkelen 
van acute levertransplantaat afstoting. Onze studie bevestigt een belangrijke rol voor IL-10 
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in de eerste fase na levertransplantatie. Nader onderzoek dient te worden gedaan of er een 
causale verband bestaat tussen IL-10 expressie/productie en het ontwikkelen van afstoting. 
Langer na transplantatie blijkt er naast een toegenomen IL-10 expressie ook een toename te 
zijn van Foxp3 expressie (hoofdstuk 8), wat suggestief is voor een accumulatie van regula-
toire T-cellen. Dit toont het onderlinge verband tussen IL-10 en Foxp3, zoals eerder reeds is 
beschreven. Patiënten die vroeg na transplantatie afstoting ontwikkelden blijken een hoger 
Foxp3 expressie in de lever te hebben dan patiënten die geen afstoting ontwikkelden. Ook 
hebben patiënten met een recidief hepatitis C infectie een hogere Foxp3 expressie. Deze 
verschillen duiden op een toegenomen aantal, of een verhoogde activiteit van regulatoire T-
cellen. Bij patiënten met hepatitis C infectie zou dit een ontsnappingsmechanisme kunnen zijn 
van het virus, waardoor deze niet adequaat geëlimineerd kan worden omdat virus-speciefieke 
T-cellen geremd worden door de regulatoire cellen. 
Deze beide studies tonen dat middels lever dunne naald biopsie het verloop van de immuno-
logische processen zoals tolerantie op een veilige manier gevolgd kunnen worden. De gevon-
den verschillen tussen patiënten suggereert een niet generaliseerbaar immuun status van de 
verschillende patiënten en pleit voor geïndividualiseerde immunosuppressieve behandeling. 
Dit proefschrift heeft regulatoire T-cellen beschreven in de lever en bloed van levertransplan-
tatie patiënten en vormt een basis voor verder onderzoek gericht op functionele capaciteiten 
van regulatoire T-cellen in relatie tot de uitkomst van een transplantatie. Een juiste balans 
tussen reactieve T-cellen en regulatoire T-cellen is cruciaal om tolerantie te verkrijgen. De 
diverse immunosuppressiva blijken verschillende effecten te hebben op de functie en overle-
ving van regulatoire T-cellen, wat pleit voor de ontwikkeling van nieuwe immunosuppressieve 
strategieën die er op gericht zijn donor transplantaat tolerantie te bewerkstelligen. Wij stellen 
dat door het bepalen van de immuun status op basis van tolerogene kenmerken, waaronder 
regulatoire T-cel activiteit en cytokine profiel in relatie tot de anti-donor reactie, bij een subset 
van de patiënten de immuunsuppressiva kunnen worden afgebouwd. Dit zou dan leiden tot 
een aanzienlijke verbetering van de kwaliteit van leven na een transplantatie.
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schapper. Veel succes met de vele projecten die lopen en zullen gaan lopen. 
Hooggeleerde heer Metselaar, beste Herold, ik weet nog als de dag van gisteren onze eerste 
ontmoeting tijdens de ‘lever’ lunch. Nederland had verloren en dan stond er ook nog eens een 
Turk voor je die heel enthousiast tolerantie zou gaan detecteren. Ik respecteer je wetenschap-
pelijke en klinische visie en dank je voor jouw inbreng en morele steun. Jij weet het probleem 
altijd direct te benaderen en te presenteren, waardoor je voor een internist verdacht wordt van 
chirurgische praktijken.
Hooggeleerde heer Ijzermans, beste Jan, ik bewonder uw klinische en wetenschappelijke 
vaardigheden. Het cysteuze cadeau tijdens een levertransplantatie zal ik nooit vergeten. Ik 
ben u dank verschuldigd om meerdere redenen en gebruik deze mogelijkheid om u te danken 
voor het beoordelen van dit proefschrift, voor uw bijdrage aan een van de artikelen en voor 
uw vele adviezen het afgelopen jaar. Ik kijk uit naar mijn retour in het Erasmus MC en hoop 
veel van u te kunnen leren. 
Hooggeleerde heer Weimar, wie had ooit gedacht dat de vader van een middelbare school 
klasgenoot 10 jaar later in mijn promotiecommissie zou zitten. Dank voor het beoordelen van 
dit proefschrift en de stimulerende gedachtewisselingen op het jaarlijkse bootcongres.
Hooggeleerde heer Laman, ook u wil ik danken voor het beoordelen van dit proefschrift en uw 
nuttige suggesties. Als expert in de immunologie bent u onmisbaar in dit gezelschap. 
Hooggeleerde heer Lerut, dank voor uw bereidheid om zitting te nemen in de commissie. In 
de afgelopen jaren heb ik meerdere artikelen van u met veel belangstelling gelezen en ik vind 
het een eer dat u deel uitmaakt van de commissie.
Weledelzeergeleerde Kazemier, beste Geert, jouw veelzijdigheid en chirurgisch vermogen 
verdienen terecht mijn ontzag voor jou. Samen op weg naar Leiden, een onvergetelijke rit, wat 
uiteindelijk heeft geleid tot een veelbelovend project. De vele mooie, leerzame momenten, de 
zuivere  koffie en de ‘Less is More’ principe zullen mij altijd bij blijven.   
Weledelzeergeleerde Baan, beste Carla, jij hebt een belangrijke bijdrage geleverd aan meer-
dere artikelen en dus ook aan het totstandkomen van dit proefschrift. Ik heb veel van je ge-
leerd en mijn dank daarvoor is groot. 
Weledelzeergeleerde Hilbrands, beste Luuk, veel dank voor de stimulerende discussies tij-
dens het jaarlijkse bootcongres en de bereidheidheid om plaats te nemen in de commissie. 
Weledelzeergeleerde Kwekkeboom, beste Jaap, dank voor de vele keren dat je kritisch naar 
mijn werk hebt gekeken en de waardevolle adviezen, die je hebt gegeven.
Weledelzeergeleerde Alwayn en weledelgeleerde Tran, beste Ian en Khe, zonder jullie bij-
drage had ik één van de kopstukken van dit proefschrift niet kunnen schrijven. Dank voor het 
verzamelen van perfusaten en de goede tijd op de afdeling. Ian, nog veel dank voor het beoor-
delen van mijn aanvraag en je adviezen. Khe, veel dank voor de leerzame tijd op 8 noord. 
Weledelgeleerde Kok, lieve Alice, waar was ik zonder jou? Jouw ongekende toewijding en 
altijd vrolijke humeur is tot op de dag van vandaag een gemis op het lab. Ik respecteer jouw 
bijdrage aan het onderzoek en wens je veel succes met je nieuwe loopbaan. 
Weledelgeleerde Tha-In, lieve Thanya, samen met Alice vormen jullie mijn ‘Angels’. As the 
Americans would say: ‘we go back, all the way to 1998’. Van de collegebanken naar het trans-
plantatielab en vandaar naar de wonderlijke wereld van de chirurgie. Ik koester de vele mooie 
momenten en wetenschappelijke discussies, die ik met jou heb gevoerd en nog steeds voer. 
Ik wens je veel succes met het afronden van je onderzoek en hoop ooit samen met jou aan 
tafel te kunnen staan. Veel dank voor je onmisbare hulp de afgelopen tijd.
Weledelzeergeleerde de Jonge, beste Jeroen, ben zeer verheugd en toch ook gerustgesteld 
dat ik jou aan mijn zijde heb. Milaan was een waanzinnig goede tijd en ik hoop op nog meer 
mooie momenten in de toekomst.    
Weledelzeergeleerde Terkivatan, lieve Tϋrkan, in de korte tijd op 7 noord/8 noord heb ik veel 
van je geleerd en wil je graag daarvoor danken. Ik ben ervan overtuigd dat je een uitstekende 
chirurg bent en wens je veel succes bij het vinden van je plekje.  
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Weledelgeleerde Claassen, beste Mark(us), dank voor de goede tijd die we samen als Treg-
lotgenoten en als kamergenoten hebben gedeeld. Het was een genot om met jou over de 
Treg filosofie te discussiëren. ‘Treg is a way of life’, right?. Veel succes met de verschillende 
veelbelovende projecten. 
Weledelgeleerde Bosma, beste Brenda, veel dank voor je bijdrage aan één van de artikelen 
en de goede tijden op de verschillende congressen. Veel succes met de afronding van je 
proefschrift en je nieuwe baan. 
Weledelgeleerde Hendrikx, beste Thijs, dank voor je inbreng aan het manuscript die we sa-
men hebben geschreven en veel succes met de laatste loodjes.   
Het MDL-lab, onder andere Martine, Angela, Jan, Anthonie, Marjolein, Antoine, Anneke, An-
dre en Linda wil ik danken voor de goede werksfeer en mooie avonden.  
Collega-onderzoekers, arts-assistenten en stafleden van de Heelkunde Erasmus MC, IKAZIA 
en MCRZ, Amici, ik dank jullie voor de stimulerende en leerzame omgeving. De chirurgencup, 
ski-weekenden en overige sociale events maakt ons een bijzonder genootschap.  
Lieve Lara, Anneloes, Sylvia, Elly, Miranda en Fatma, zonder jullie was dit allemaal niet moge-
lijk geweest, heel veel dank voor jullie inzet. In het bijzonder wil ik Elly danken die een cruciale 
rol heeft gespeeld bij de inclusie van patiënten voor meerdere studies. Tevens worden bij 
deze alle patiënten bedankt voor participatie aan de verschillende studies.
Mijn twee beste vrienden, Elwin Bes en Ayhan ‘Baykus’ Beyazit, ik had geen mooier cover en 
lay-out kunnen verzinnen en complimenteer jullie met dit sublieme resultaat. Elwin, jouw crea-
tieve geest kan niet worden evenaard. Inmiddels hebben we al een aardige historie samen en 
het verhaal van G1 en G2 wordt hoe langer, hoe mooier. Ayhan, ik ken je al mijn hele leven en 
altijd als ik je nodig heb sta je voor me klaar. De vele zware, doch memorabele nachten, die 
we samen in dit werk hebben zitten zal ik nooit vergeten. Woorden kunnen niet beschrijven 
hoe groot mijn dank is voor jullie vriendschap.
Vrienden, lieve Rosa, Maria, Edson, Karsten, Stefan, Ivana, Ali en Alime geweldig dat jullie er 
altijd zijn voor de mooie en minder mooie momenten des levens. Met een ieder van jullie heb 
ik een bijzondere band en ik ben blij dat ik jullie tot mijn vriendenkring mag rekenen.
Lieve ouders, mijn grote broertje en lieve zusje, tot de dag van vandaag hebben jullie me altijd 
liefdevol geholpen en gesteund. Dit proefschrift en al het andere had ik zonder jullie niet kun-
nen bereiken. Aytur, ik ben ervan overtuigd dat jij een uitstekende bouwkundige zal worden en 
wens je veel succes met je opleiding. BetϋI, New York wacht op ons, dus....
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